Phone
+61 2 9385 0877
E-mail
gmatthews@kirby.unsw.edu.au
Young C; Singh M; Jackson KJL; Field MA; Peters TJ; Angioletti-Uberti S; Frenkel D; Ravishankar S; Gupta M; Wang JJ; Agapiou D; Faulks ML; Al-Eryani G; Luciani F; Gordon TP; Reed JH; Danta M; Carr A; Kelleher AD; Dore GJ; Matthews G; Brink R; Bull RA; Suan D; Goodnow CC, 2024, Self-reactive B cells traverse a perfect storm of somatic mutagenesis to cause a virus-induced autoimmune disease, , http://dx.doi.org/10.1101/2024.01.07.574561
2024
Phetsouphanh C; Jacka B; Ballouz S; Jackson KJL; Wilson D; Manandhar B; Klemm V; Tan H-X; Wheatley A; Aggarwal A; Akerman A; Milogiannakis V; Starr M; Cunningham P; Turville S; Kent S; Byrne A; Brew B; Darley D; Dore G; Kelleher A; Matthews G, 2023, Improvement of immune dysregulation and health-related quality of life in individuals with long COVID at 24-months following SARS-CoV-2 infection, , http://dx.doi.org/10.1101/2023.08.27.23294704
2023
Dharan NJ; Sasson SC; Ahlenstiel G; Andersen CR; Bloch M; Buckland G; Hamad N; Han WM; Kelleher AD; Long GV; Matthews GV; Mina MM; Papot E; Petoumenos K; Swaminathan S; Withers B; Yun J; Polizzotto MN, 2023, Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia, , http://dx.doi.org/10.1101/2023.08.17.23293358
2023
Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Kidinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Coppola G; Yeang M; Jean T; Foster C; Hoppe AC; Ling Munier M; Darley D; Churchill M; Starck D; Christ D; Matthews G; Rawlinson W; Kelleher A; Turville S, 2022, SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, , http://dx.doi.org/10.1101/2022.07.07.22277128
2022
Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks M; Law H; Danwilai T; Starr M; Munier ML; Christ D; Singh M; Croucher P; Brilot-Turville F; Turville S; Phan TG; Dore G; Darley D; Cunningham P; Matthews G; Kelleher A; Zaunders J, 2022, High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells, , http://dx.doi.org/10.1101/2022.07.22.22277947
2022
Aggarwal A; Stella A; Akerman A; Walker G; Milogiannakis V; McAllery S; Esneau C; Silva MR; Lu Y; Forster C; Hal SV; Mathivanan V; Fitcher C; Hoppe AC; Munier ML; Darley D; Matthews G; Starck D; Robosa R; Bartlett N; Rawlinson W; Kelleher A; Turville S, 2022, Rapid isolation and resolution immune evasion and viral fitness across contemporary SARS-CoV-2 variants, , http://dx.doi.org/10.21203/rs.3.rs-1210846/v1
2022
Cysique L; Jakabek D; Bracken S; Allen-Davidian Y; Heng B; Chow S; Dehhaghi M; Pires AS; Darley D; Byrne A; Phetsouphanh C; Kelleher A; Dore G; Matthews G; Guillemin G; Brew B, 2022, Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study, , http://dx.doi.org/10.1101/2022.06.07.22276020
2022
Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fitcher C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG, 2022, Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sublineages in the face of maturing antibody breadth at the population level, , http://dx.doi.org/10.1101/2022.12.06.22283000
2022
Aggarwal A; Stella AO; Walker G; Akerman A; Milogiannakis V; Brilot F; Amatayakul-Chantler S; Roth N; Coppola G; Schofield P; Jackson J; Henry J; Mazigi O; Langley D; Lu Y; Forster C; McAllery S; Mathivanan V; Fichter C; Hoppe AC; Munier ML; Jack H-M; Cromer D; Darley D; Matthews G; Christ D; Khoury D; Davenport M; Rawlinson W; Kelleher A; Turville S, 2021, SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, , http://dx.doi.org/10.1101/2021.12.14.21267772
2021
Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Kidinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Yeang M; Jean T; Foster C; Hoppe AC; Munier ML; Darley DR; Churchill M; Starck D; Christ D; Matthews G; Rawlinson W; Kelleher A; Turville S, SARS-CoV-2 Omicron BA.5: Evolving Tropism and Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of Concern, , http://dx.doi.org/10.2139/ssrn.4157473
Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Rowling D; Doong N; Jackson E; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study, , http://dx.doi.org/10.2139/ssrn.3269607
Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua N; fierer D; Chromy D; Rockstroh JK; Martin T; Ingiliz P; Hung C-C; Dore GJ; Martinello M; Matthews G, Hepatitis C Reinfection Risk Following Successful Therapy Among People Living with HIV: A Global Systematic Review, Meta-Analysis, and Meta-Regression, , http://dx.doi.org/10.2139/ssrn.3958916
Koopsen J; Matthews G; Rockstroh JK; Applegate TL; Bhagani SR; Grebely J; Rauch A; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard ME; Dore GJ; Schinkel J; van der Valk M; Study Group REACT, Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection, , http://dx.doi.org/10.2139/ssrn.4125248
Nyein PP; Tillakeratne SJ; Phyu S; Myint Myint Y; Lwin MM; Htike KL; Aung MT; Applegate TL; Hanson J; Matthews G; Lin KS, Evaluation of Simplified HCV Diagnostics in HIV/HCV Co-Infected Patients in Myanmar (Simplified Monitoring Myanmar SM <sub>2</sub> Study), , http://dx.doi.org/10.2139/ssrn.4257640
Harney BL; Sacks-Davis R; van Santen DK; Traeger MW; Wilkinson AL; Asselin J; Fairley CK; Roth N; Bloch M; Matthews GV; Donovan B; Guy R; Stoové M; Hellard ME; Doyle JS, 2024, 'Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020', Liver International, 44, pp. 1024 - 1031, http://dx.doi.org/10.1111/liv.15841
2024
Bin Usman Shah SH; Alavi M; Hajarizadeh B; Matthews GV; Martinello M; Danta M; Amin J; Law MG; George J; Valerio H; Dore GJ, 2024, 'Corrigendum to “Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales” [JHEP Reports 4 (2022)] (JHEP Reports (2022) 4(10), (S2589555922001240), (10.1016/j.jhepr.2022.100552))', JHEP Reports, 6, http://dx.doi.org/10.1016/j.jhepr.2024.101022
2024
Harney BL; Sacks-Davis R; Agius P; van Santen DK; Traeger MW; Wilkinson AL; Asselin J; Fairley CK; Roth N; Bloch M; Matthews GV; Donovan B; Guy R; Stoové M; Hellard ME; Doyle JS; Aung HL; Baillie G; Bastian L; Bateson D; Boyd M; Carter A; Cogle A; Costello J; Dimech W; El-Hayek C; Ellard J; Franklin L; Hocking J; Kim J; Nguyen L; Nguyen T; Nolan D; O’Connor C; Patel P; Pendle S; Polkinghorne V; Reed P; Ryder N; Selvey C; Walker M; Watson N, 2024, 'Risk of Primary Incident Hepatitis C Infection Following Bacterial Sexually Transmissible Infections Among Gay and Bisexual Men in Australia From 2016 to 2020', Open Forum Infectious Diseases, 11, http://dx.doi.org/10.1093/ofid/ofae099
2024
van Santen DK; Stewart A; Doyle JS; Stoové MA; Asselin J; Klein MB; Young J; Berenguer J; Jarrin I; Lacombe K; Wittkop L; Leleux O; Salmon D; Bonnet F; Rauch A; Mugglin C; Matthews G; Prins M; Smit C; Boyd A; van der Valk M; Sacks-Davis R; Hellard ME, 2024, 'Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)', International Journal of Epidemiology, 53, http://dx.doi.org/10.1093/ije/dyad154
2024
Marshall AD; Willing AR; Kairouz A; Cunningham EB; Wheeler A; O'Brien N; Perera V; Ward JW; Hiebert L; Degenhardt L; Hajarizadeh B; Colledge S; Hickman M; Jawad D; Lazarus JV; Matthews GV; Scheibe A; Vickerman P; Dore GJ; Grebely J; Sargsyants N; Suleymanova L; Salkic N; Simonova M; Nemeth-Blazic T; Mravcik V; Kivimets K; Salupere R; Butsashvili M; Soselia G; Makara M; Tolmane I; Jancorienė L; Stratulat S; Flisiak R; Gheorghe L; Cernat R; Lakhov A; Stanevich O; Jarcuska P; Peck-Radosavljevic M; Robaeys G; Øvrehus A; Foster G; Sutinen J; Farkkila M; Rautiainen H; Vuoti S; Nikolova D; Pawlotsky JM; Rockstroh J; Sypsa V; Papatheodoridis G; Olafsson S; Feeney E; Teti E; Seguin-Devaux C; Pocock J; Reiff S; McDougall N; Van der Valk M; Dalgard O; Tato Marinho R; Dillon J; Peters E; Bojovic K; Matičič M; Kåberg M; Bruggmann P; Healy B; Chong VH; Yi S; Tucker J; Pasaribu LR; Tanaka J; Ashley EA; Abu Hassan MR; Mohammed NS; Chan HK; Gidaagaya S; Kyi KP; Hyung Joon K; Chin B; Baladjay PC; Kao JH; Wansom T; da Cruz B; Flower B; Ehsan E; Al Mahtab M; Khandu L; Bhadoria AS; Alavi M; KC P; Hamid S; Biryukov S; Alymbaeva D; Alaei A; Bakieva S; Flichman D, 2024, 'Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions', The Lancet Gastroenterology and Hepatology, 9, pp. 366 - 382, http://dx.doi.org/10.1016/S2468-1253(23)00335-7
2024
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M; Ke T; Zhang Y; Pedrana A; Asselin J; Dawe J; Wilkinson A; Schinkel J; Sogni P; Esterle L; Gilbert C; Merchadou L; Gillet S; Khan C; Le Marec F; Perrier A; Shaw I; Martinello M; Applegate T; Carson J; Harney B; Bryant M; Jarrin Vera I; Alejos B; Lazarus JV; Moreno C; Izquierdo R; Rava M; Wang S; Lumia J; Pexos C; Peiris H; Saeed S; Moodie E; Pick N; Conway B; Hull M; Wong A; Gill J; Barrett L; Cohen J; Cox J; Cote P; Haider S; Rouleau D; Vachon ML; Rachlis A; Sandre R; Walmsley S; Sadr A; Cooper C; Sanche S; Salazar-Viscaya L; Kusejko K; Hage K; Requena MB; Girard PM; Brucker M; Vincensini JP, 2024, 'Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies', The Lancet HIV, 11, pp. e106 - e116, http://dx.doi.org/10.1016/S2352-3018(23)00267-9
2024
Stewardson AJ; Davis JS; Dunlop AJ; Tong SYC; Matthews GV, 2024, 'How I manage severe bacterial infections in people who inject drugs', Clinical Microbiology and Infection, 30, pp. 877 - 882, http://dx.doi.org/10.1016/j.cmi.2024.01.022
2024
Singh KP; Avihingsanon A; Zerbato JM; Zhao W; Braat S; Tennakoon S; Rhodes A; Matthews GV; Fairley CK; Sasadeusz J; Crane M; Audsley J; Lewin SR, 2024, 'Predictors of liver disease progression in people living with HIV-HBV co-infection on antiretroviral therapy', eBioMedicine, 102, http://dx.doi.org/10.1016/j.ebiom.2024.105054
2024
Phetsouphanh C; Jacka B; Ballouz S; Jackson KJL; Wilson DB; Manandhar B; Klemm V; Tan HX; Wheatley A; Aggarwal A; Akerman A; Milogiannakis V; Starr M; Cunningham P; Turville SG; Kent SJ; Byrne A; Brew BJ; Darley DR; Dore GJ; Kelleher AD; Matthews GV, 2024, 'Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-47720-8
2024
Matthews G; Jacoby S; Borok M; Eriobu N; Kaplan R; Kumarasamy N; Bennet JA; Avihingsanon A; Chetchotisakd P; Wagner Cardoso S; Azwa I; Losso M; Brown D; Arlinda D; Hutchinson J; Kelleher A; Cisse M; Dao S; Polizzotto M; Emery S; Law M; Papot E; Karyana M; Lupo S; Solari AM; Grinsztejn B; Wolff M; Andrade-Villanueva J; Mosqueda Gómez JL; Chow TS; Mohapi L; Yunihastuti E; Hadi U; Katu S; Subronto YW; Lane HC; Perelis L, 2024, 'Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial', The Lancet HIV, http://dx.doi.org/10.1016/S2352-3018(24)00089-4
2024
Casey JL; Dore GJ; Grebely J; Matthews GV; Cherepanov V; Martinello M; Marks P; Janssen HLA; Hansen BE; Kaul R; MacParland SA; Gehring AJ; Feld JJ, 2023, 'Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection', Journal of Viral Hepatitis, 30, pp. 64 - 72, http://dx.doi.org/10.1111/jvh.13761
2023
Carson JM; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia', Journal of Hepatology, 78, pp. 260 - 270, http://dx.doi.org/10.1016/j.jhep.2022.09.011
2023
Hall SAL; Burns GS; Mooney BJ; Millen R; Morris R; Vogrin S; Sundararajan V; Ratnam D; Levy MT; Lubel JS; Nicoll AJ; Strasser SI; Sievert W; Desmond PV; Ngu MC; Angus P; Sinclair M; Meredith C; Matthews G; Revill PA; Jackson K; Littlejohn M; Bowden S; Locarnini SA; Thompson AJ; Visvanathan K, 2023, 'Hepatitis B Virus Flares after Nucleot(s)ide Analogue Cessation Are Associated with Activation of Toll-Like Receptor Signaling Pathways', Journal of Infectious Diseases, 227, pp. 123 - 132, http://dx.doi.org/10.1093/infdis/jiac375
2023
Cheng Q; Cunningham EB; Shih S; Amin J; Bruneau J; Artenie AA; Powis J; Litwin AH; Cooper C; Dalgard O; Hellard M; Bruggmann P; Marks P; Lacombe K; Stedman C; Read P; Hajarizadeh B; Dunlop AJ; Conway B; Feld JJ; Dore GJ; Grebely J; Dore G; Crawford S; Swan T; Byrne J; Coordinating Centre—Amanda Erratt ML; Marks P; Shaw I; Siriragavan S; Quiene S; Petoumenos K; Schmid P; Castro E; Moriggia A; Daulouede JP; Fraser C; Feld J; Gane E; Matthews G; Kronborg I; Shaw D; Norton B; Thurnheer MC; Weltman M; Dillon J; Kessler S; Knapp C; Oprandi L; Messina P; Pantic M; Le Cam M; Maitre C; Andreassen J; Melkeraaen I; Tollefsen MM; Pagarigan H; Milne R; Mason K; Kaznowski D; Zou L; Bouchard R; Kotsoros B; Muir M; Milloy J; Oliver V; Noonan T; Sevehon A; Hazelwood S; Hall M; Hagenauer M; Liddle R; Ferguson C; Agyemang L; Patel H; Soloway I; Cerocchi O; Lacalamita M; Fragomeli V; Gilliver R; Lothian R; Cleary S; Johnston L; Middleton S; D'Amico R; McGovern B; Anderson J; Zhong Z; Keane F; Tatsch F; Brainard D; McHutchison J, 2023, 'Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs', Value in Health, 26, pp. 883 - 892, http://dx.doi.org/10.1016/j.jval.2022.12.016
2023
Jessica HB; Carson J; Scott M; Patricia C; Nelson R; Helen VG; Phillip R; Hanson J; Robert M; Matthews G; Dore GJ; Martinello M; Read P, 2023, 'Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C)', Journal of Viral Hepatitis, 30, pp. 386 - 396, http://dx.doi.org/10.1111/jvh.13803
2023
van Santen DK; Sacks-Davis R; Stewart A; Boyd A; Young J; van der Valk M; Smit C; Rauch A; Braun DL; Jarrin I; Berenguer J; Lazarus JV; Lacombe K; Requena MB; Wittkop L; Leleux O; Salmon D; Bonnet F; Matthews G; Doyle JS; Spelman T; Klein MB; Prins M; Asselin J; Stoové MA; Hellard M, 2023, 'Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019', eClinicalMedicine, 56, http://dx.doi.org/10.1016/j.eclinm.2022.101810
2023
Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG, 2023, 'Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level', eBioMedicine, 90, http://dx.doi.org/10.1016/j.ebiom.2023.104545
2023
Carson J; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016-2021', Hepatology Communications, 7, pp. e0125, http://dx.doi.org/10.1097/HC9.0000000000000125
2023
Carson JM; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'Corrigendum to ‘National trends in retreatment of HCV due to reinfection or treatment failure in Australia’ (J Hepatol [2023] 260–270) (Journal of Hepatology (2023) 78(2) (260–270), (S016882782203118X), (10.1016/j.jhep.2022.09.011))', Journal of Hepatology, 78, pp. 1084, http://dx.doi.org/10.1016/j.jhep.2023.02.020
2023
Manoharan L; Latham NH; Munari SC; Traeger MW; Menon V; Luhmann N; Baggaley R; Macdonald V; Verster A; Siegfried N; Matthews GV; Stoové M; Hellard ME; Doyle JS, 2023, 'Immediate treatment for recent hepatitis C infection in people with high-risk behaviors: a systematic review and meta-analysis', Hepatology Communications, 7, http://dx.doi.org/10.1097/HC9.0000000000000082
2023
Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV, 2023, 'Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study', The Lancet Public Health, 8, pp. e294 - e304, http://dx.doi.org/10.1016/S2468-2667(23)00056-7
2023
Nyein PP; Tillakeratne S; Phyu S; Yee MM; Lwin MM; Htike KL; Aung MT; Grebely J; Applegate T; Hanson J; Matthews G; Lin KS, 2023, 'Evaluation of Simplified HCV Diagnostics in HIV/HCV Co-Infected Patients in Myanmar', Viruses, 15, pp. 521, http://dx.doi.org/10.3390/v15020521
2023
Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Valerio H; Dore GJ, 2023, 'Liver-related mortality among people with hepatitis B and C: Evaluation of definitions based on linked healthcare administrative datasets', Journal of Viral Hepatitis, 30, pp. 520 - 529, http://dx.doi.org/10.1111/jvh.13824
2023
Valerio H; Alavi M; Marshall AD; Hajarizadeh B; Amin J; Law M; Tillakeratne S; George J; Degenhardt L; Grebely J; Matthews GV; Dore GJ, 2023, 'Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study', Drug and Alcohol Review, http://dx.doi.org/10.1111/dar.13688
2023
Cysique LA; Jakabek D; Bracken SG; Allen-Davidian Y; Heng B; Chow S; Dehhaghi M; Staats Pires A; Darley DR; Byrne A; Phetsouphanh C; Kelleher A; Dore GJ; Matthews GV; Guillemin GJ; Brew BJ, 2023, 'The kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC', Annals of Clinical and Translational Neurology, 10, pp. 1338 - 1352, http://dx.doi.org/10.1002/acn3.51825
2023
Schiavone B; Dore GJ; Stone E; Matthews GV; Darley DR, 2023, 'An update on long COVID and its management', Medicine Today, 24, pp. 37 - 43
2023
Martinello M; Carson JM; Van Der Valk M; Rockstroh JK; Ingiliz P; Hellard M; Nelson M; Lutz T; Bhagani S; Kim AY; Hull M; Cordes C; Moon J; Feld JJ; Gane E; Rauch A; Bruneau J; Tu E; Applegate T; Grebely J; Dore GJ; Matthews GV, 2023, 'Reinfection incidence and risk among people treated for recent hepatitis C virus infection', AIDS, 37, pp. 1883 - 1890, http://dx.doi.org/10.1097/QAD.0000000000003651
2023
Usman Shah SHB; Valerio H; Hajarizadeh B; Alavi M; Matthews G; Dore G, 2023, 'Cascade of care among people with an HBV notification in New South Wales, Australia, including diagnosis, specialist assessment, and treatment uptake', Journal of Hepatology, 78, pp. S910 - S910, http://dx.doi.org/10.1016/s0168-8278(23)02932-x
2023
Anagnostou N; Archuleta S; Athan E; Barina L; Best E; Bloomfield M; Bostock J; Botheras C; Bowen A; Britton P; Burden H; Campbell A; Carter H; Cheng M; Chew KL; Chong IRLM; Coombs G; Daley P; Daneman N; Davies J; Davis J; Dishon-Benattar Y; Dotel R; Dunlop A; Flack F; Flanagan K; Foo H; Ghanem-Zoubi N; Giulieri S; Goodman A; Grant J; Gregson D; Guy S; Gwee A; Hardy E; Henderson A; Heriot G; Howden B; Hudson F; Johnstone J; Kalimuddin S; de Kretser D; Kwa A; Lee T; Legg A; Lewis R; Llewelyn M; Lumley T; Lye D; MacFadden D; Mahar R; Malhame I; Marks M; Marsh J; Martinello M; Matthews G; McArthur C; McGlothlin A; McKew G; McMullan B; McQuilten Z; Milliken E; Mora J; Morpeth S; Murthy S; Nourse C; O'Sullivan M; Paterson D; Paul M; Petersiel N; Petrella L; Pett S; Price D; Roberts J; Robinson JO; Rogers B; Saville B; Scarborough M; Scheetz M; Scheuerman O; Schwartz K; Smith S; Snelling T; Soares M; Sommerville C; Stewardson A; Stone N; Sud A; Tilley R; Tong S; Turner R; Underwood J; van Hal S; Voss L; Walls G; Webb R; Webb S; Whiteway L; Wilson H; Wuerz T; Yahav D, 2023, 'The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe (vol 75, pg 2027, 2022)', CLINICAL INFECTIOUS DISEASES, http://dx.doi.org/10.1093/cid/ciac730
2023
Koopsen J; Matthews G; Rockstroh J; Applegate TL; Bhagani S; Rauch A; Grebely J; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard M; Dore GJ; Schinkel J; van der Valk M; Adams T; Amjad S; Appelhans C; Becker B; Bouchard R; Braun D; Bruelisauer C; Calcagnile S; Carroll A; Cerocchi O; Chronister K; Cordes C; Dore G; Evans F; Fedele S; Ferguson C; Fraser C; Ganase B; Gane E; George V; Gerlach C; Gilleece Y; Gilliver R; Grube C; Gustafson J; Haas A; Hagenauer M; Harris M; Helder J; Hirter D; Hull M; Katz S; Kim A; Kotsoros B; Lacalamita M; Lindergard G; Lutz T; Macabodbod L; Manz M; Marks P; Messina P; Mohrmann K; Monnich C; Moon J; Moriggia A; Morris G; Morrish T; Nelson M; Oliver V; Patterson J; Peters M; Petoumenos K; Porretta H; Raymode P; Read P; Reece S; Saidi A; Sasadeusz J; Scherler P; Schröder R; Selfridge M; Sevehon A; Shaw D; Sulkowski M; Tamaddoni M; Thunder O; Thurnheer MC; Tu E; Ustianowski A; Witele E, 2023, 'Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis', The Lancet Microbe, 4, pp. e622 - e631, http://dx.doi.org/10.1016/S2666-5247(23)00108-8
2023
Martinello M; Bhagani S; Shaw D; Orkin C; Cooke G; Gane E; Iser D; Ustianowski A; Kulasegaram R; Stedman C; Tu E; Grebely J; Dore GJ; Nelson M; Matthews GV, 2023, 'Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study', JHEP Reports, 5, http://dx.doi.org/10.1016/j.jhepr.2023.100867
2023
Shah SHBU; Valerio H; Hajarizadeh B; Matthews G; Alavi M; Dore GJ, 2023, 'Cascade of care among people with hepatitis B in New South Wales, Australia', Journal of Viral Hepatitis, 30, pp. 926 - 938, http://dx.doi.org/10.1111/jvh.13881
2023
Martinello M; Naggie S; Rockstroh JK; Matthews GV, 2023, 'Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review', Clinical Infectious Diseases, 77, pp. S238 - S244, http://dx.doi.org/10.1093/cid/ciad344
2023
Carson JM; Barbieri S; Cunningham E; Mao E; van der Valk M; Rockstroh JK; Hellard M; Kim A; Bhagani S; Feld JJ; Gane E; Thurnheer MC; Bruneau J; Tu E; Dore GJ; Matthews GV; Martinello M, 2023, 'Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study', Journal of the International AIDS Society, 26, pp. e26168, http://dx.doi.org/10.1002/jia2.26168
2023
Dodd S; Mohebbi M; O'Donohue J; Matthews G; Darley DR; Berk M, 2023, 'Psychiatric sequelae after SARS-Cov-2 infection: Trajectory, predictors and associations in a longitudinal Australian cohort', Acta Neuropsychiatrica, http://dx.doi.org/10.1017/neu.2023.45
2023
Hage K; van de Kerkhof M; Boyd A; Carson JM; Newsum AM; Matser A; van der Valk M; Brinkman K; Arends JE; Lauw FN; Rijnders BJA; van Eeden A; Martinello M; Matthews GV; Schinkel J; Prins M, 2023, 'Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV: Results from a Case–Control Diagnostic Validation Study', Pathogens, 12, pp. 1248, http://dx.doi.org/10.3390/pathogens12101248
2023
Dharan NJ; Sasson SC; Ahlenstiel G; Andersen CR; Bloch M; Buckland G; Hamad N; Han WM; Kelleher AD; Long GV; Matthews GV; Mina MM; Papot E; Petoumenos K; Swaminathan S; Withers B; Yun J; Polizzotto MN, 2023, 'Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia', PLoS ONE, 18, http://dx.doi.org/10.1371/journal.pone.0289907
2023
Smith MZ; Turner M; Haurat J; Thevarajan I; Denholm J; Tong SY; Matthews GV; Bull RA; Martinello M; McMahon J; Imrie A; Pillai PE, 2023, 'The APPRISE Virtual Biobank for Infectious Diseases', Communicable diseases intelligence (2018), 47, http://dx.doi.org/10.33321/cdi.2023.47.66
2023
Morpeth SC; Venkatesh B; Totterdell JA; McPhee GM; Mahar RK; Jones M; Bandara M; Barina LA; Basnet BK; Bowen AC; Burke AJ; Cochrane B; Denholm JT; Dhungana A; Dore GJ; Dotel R; Duffy E; Dummer J; Foo H; Gilbey TL; Hammond NE; Hudson BJ; Jha V; Jevaji PR; John O; Joshi R; Kang G; Kaur B; Kim S; Das SK; Lau JSY; Littleford R; Marsh JA; Marschner IC; Matthews G; Maze MJ; McArthur CJ; McFadyen JD; McMahon JH; McQuilten ZK; Molton J; Mora JM; Mudaliar V; Nguyen V; O'Sullivan MVN; Pant S; Park JE; Paterson DL; Price DJ; Raymond N; Rees MA; Robinson JO; Rogers BA; Ryu W-S; Sasadeusz J; Shum O; Snelling TL; Sommerville C; Trask N; Lewin SR; Hills TE; Davis JS; Roberts JA; Tong SYC, 2023, 'A Randomized Trial of Nafamostat for Covid-19.', NEJM Evid, 2, pp. EVIDoa2300132, http://dx.doi.org/10.1056/EVIDoa2300132
2023
Lundgren JD; Babiker AG; Sharma S; Grund B; Phillips AN; Matthews G; Kan VL; Aagaard B; Abo I; Alston B; Arenas-Pinto A; Avihingsanon A; Badal-Faesen S; Brites C; Carey C; Casseb J; Clarke A; Collins S; Corbelli GM; Dao S; Denning ET; Emery S; Eriobu N; Florence E; Furrer H; Fätkenheuer G; Gerstoft J; Gisslén M; Goodall K; Henry K; Horban A; Hoy J; Hudson F; Azwa RISR; Kedem E; Kelleher A; Kityo C; Klingman K; Rosa AL; Leturque N; Lifson AR; Losso M; Lutaakome J; Madero JS; Mallon P; Mansinho K; Filali KME; Molina J-M; Murray DD; Nagalingeswaran K; Nozza S; Ormaasen V; Paredes R; Peireira LC; Pillay S; Polizzotto MN; Raben D; Rieger A; Sanchez A; Schechter M; Sedlacek D; Staub T; Touloumi G; Turner M; Madruga JV; Vjecha M; Wolff M; Wood R; Zilmer K; Lane HC; Neaton JD; INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group , 2023, 'Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.', NEJM Evid, 2, http://dx.doi.org/10.1056/evidoa2200302
2023
Matuozzo D; Talouarn E; Marchal A; Zhang P; Manry J; Seeleuthner Y; Zhang Y; Bolze A; Chaldebas M; Milisavljevic B; Gervais A; Bastard P; Asano T; Bizien L; Barzaghi F; Abolhassani H; Abou Tayoun A; Aiuti A; Alavi Darazam I; Allende LM; Alonso-Arias R; Arias AA; Aytekin G; Bergman P; Bondesan S; Bryceson YT; Bustos IG; Cabrera-Marante O; Carcel S; Carrera P; Casari G; Chaïbi K; Colobran R; Condino-Neto A; Covill LE; Delmonte OM; El Zein L; Flores C; Gregersen PK; Gut M; Haerynck F; Halwani R; Hancerli S; Hammarström L; Hatipoğlu N; Karbuz A; Keles S; Kyheng C; Leon-Lopez R; Franco JL; Mansouri D; Martinez-Picado J; Metin Akcan O; Migeotte I; Morange PE; Morelle G; Martin-Nalda A; Novelli G; Novelli A; Palabiyik F; Pan-Hammarström Q; de Diego RP; Planas-Serra L; Pleguezuelo DE; Prando C; Pujol A; Reyes LF; Rivière JG; Rodriguez-Gallego C; Rojas J; Rovere-Querini P; Schlüter A; Shahrooei M; Sobh A; Soler-Palacin P; Tandjaoui-Lambiotte Y; Tipu I; Tresoldi C; Troya J; van de Beek D; Zatz M; Zawadzki P; Al-Muhsen SZ; Alosaimi MF; Alsohime FM; Baris-Feldman H; Butte MJ; Constantinescu SN; Cooper MA; Dalgard CL; Fellay J; Heath JR; Lau YL; Lifton RP; Maniatis T; Mogensen TH; von Bernuth H; Lermine A; Vidaud M; Boland A, 2023, 'Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19', Genome Medicine, 15, http://dx.doi.org/10.1186/s13073-023-01173-8
2023
Thompson AJ; Jackson K; Bonanzinga S; Hall SAL; Hume S; Burns GS; Sundararajan V; Ratnam D; Levy MT; Lubel J; Nicoll AJ; Strasser SI; Sievert W; Desmond PV; Ngu MC; Sinclair M; Meredith C; Matthews G; Revill PA; Littlejohn M; Bowden DS; Canchola JA; Torres J; Siew P; Lau J; Brot BL; Kuchta A; Visvanathan K, 2023, 'Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants', Hepatology Communications, 7, http://dx.doi.org/10.1097/HC9.0000000000000188
2023
Phetsouphanh C; Darley DR; Wilson DB; Howe A; Munier CML; Patel SK; Juno JA; Burrell LM; Kent SJ; Dore GJ; Kelleher AD; Matthews GV, 2022, 'Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection', Nature Immunology, 23, pp. 210 - 216, http://dx.doi.org/10.1038/s41590-021-01113-x
2022
Aggarwal A; Stella AO; Walker G; Akerman A; Esneau C; Milogiannakis V; Burnett DL; McAllery S; Silva MR; Lu Y; Foster CSP; Brilot F; Pillay A; Van Hal S; Mathivanan V; Fichter C; Kindinger A; Hoppe AC; Munier ML; Amatayakul-Chantler S; Roth N; Coppola G; Symonds GP; Schofield P; Jackson J; Lenthall H; Henry JY; Mazigi O; Jäck HM; Davenport MP; Darley DR; Matthews GV; Khoury DS; Cromer D; Goodnow CC; Christ D; Robosa R; Starck DJ; Bartlett NW; Rawlinson WD; Kelleher AD; Turville SG, 2022, 'Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia', Nature Microbiology, 7, pp. 896 - 908, http://dx.doi.org/10.1038/s41564-022-01135-7
2022
Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG, 2022, 'SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern', eBioMedicine, 84, http://dx.doi.org/10.1016/j.ebiom.2022.104270
2022
Amin J; Vaccher S; Templeton DJ; Bavinton B; Jin F; Zablotska I; Matthews G; Ogilvie E; Yeung B; Ooi C; Dharan N; Baker DA; Read P; Guy R; Grulich AE, 2022, 'Low Prior Exposure and Incidence of Hepatitis C in Human Immunodeficiency Virus–Negative Gay and Bisexual Men Taking Preexposure Prophylaxis (PrEP): Findings from the Expanded PrEP Implementation in Communities–New South Wales Prospective Implementation Study', Clinical Infectious Diseases, 75, pp. 1497 - 1502, http://dx.doi.org/10.1093/cid/ciac231
2022
Hernández Cordero AI; Yang CX; Yang J; Li X; Horvath S; Shaipanich T; MacIsaac J; Lin D; McEwen L; Kobor MS; Guillemi S; Harris M; Lam W; Lam S; Obeidat M; Novak RM; Hudson F; Klinker H; Dharan N; Montaner J; Man SFP; Kunisaki K; Sin DD; Leung JM; Baker JV; Duprez D; Carr A; Hoy J; Dolan M; Telenti A; Grady C; Matthews G; Rockstroh J; Belloso WH; Kagan JM; Wright E; Brew B; Price RW; Robertson K; Cysique L; Connett JE; Niewoehner DE; Endpoint Review Committee ; Lifson A; Davey RT; Gatell JM; Pedersen C; Prineas R; Worley J, 2022, 'The relationship between the epigenetic aging biomarker “grimage” and lung function in both the airway and blood of people living with HIV: An observational cohort study', eBioMedicine, 83, http://dx.doi.org/10.1016/j.ebiom.2022.104206
2022
Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B, 2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819, http://dx.doi.org/10.1093/cid/ciac246
2022
Weld ED; Astemborski J; Kirk GD; Sulkowski MS; Katz S; Rothman R; Solomon SS; Matthews GV; Hsieh YH; Verma M; Traverso G; Swindells S; Owen A; Feld J; Flexner C; Mehta SH; Thomas DL, 2022, 'Preferences of Persons with or at Risk for Hepatitis C for Long-Acting Treatments', Clinical Infectious Diseases, 75, pp. 3 - 10, http://dx.doi.org/10.1093/cid/ciab913
2022
Lubel JS; Strasser SI; Thompson AJ; Cowie BC; MacLachlan J; Allard NL; Holmes J; Kemp WW; Majumdar A; Iser D; Howell J; Matthews GV, 2022, 'Australian consensus recommendations for the management of hepatitis B', Medical Journal of Australia, 216, pp. 478 - 486, http://dx.doi.org/10.5694/mja2.51430
2022
Howe AYM; Rodrigo C; Cunningham EB; Douglas MW; Dietz J; Grebely J; Popping S; Sfalcin JA; Parczewski M; Sarrazin C; de Salazar A; Fuentes A; Sayan M; Quer J; Kjellin M; Kileng H; Mor O; Lennerstrand J; Fourati S; Di Maio VC; Chulanov V; Pawlotsky JM; Harrigan PR; Ceccherini-Silberstein F; Garcia F; Martinello M; Matthews G; Fernando FF; Esteban JI; Müllhaupt B; Wiesch JSZ; Buggisch P; Neumann-Haefelin C; Berg T; Berg CP; Schattenberg JM; Moreno C; Stauber R; Lloyd A; Dore G; Applegate T; Ignacio J; Garcia-Cehic D; Gregori J; Rodriguez-Frias F; Rando A; Gozlan Y; Angelico M; Andreoni M; Babudieri S; Bertoli A; Cento V; Coppola N; Craxì A; Paolucci S; Parruti G; Pasquazzi C; Perno CF; Teti E; Vironet C; Lannergård A; Duberg AS; Aleman S; Gutteberg T; Soulier A; Gourgeon A; Chevaliez S; Pol S; Carrat F; Salmon D; Kaiser R; Knopes E; Gomes P; de Kneght R; Rijnders B; Poljak M; Lunar M; Usubillaga R; Seguin_Devaux C; Tay E; Wilson C; Wang DS; George J; Kok J; Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A, 2022, 'Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals', JHEP Reports, 4, pp. 100462, http://dx.doi.org/10.1016/j.jhepr.2022.100462
2022
Krishnan A; Ellenberger KA; Phetsouphanh C; Kelleher AP; Matthews GV; Darley DR; Holloway CJ, 2022, 'Myocardial fibrosis occurs in non-hospitalised patients with chronic symptoms after COVID-19', IJC Heart and Vasculature, 39, http://dx.doi.org/10.1016/j.ijcha.2022.100964
2022
Hall SAL; Burns GS; Anagnostou D; Vogrin S; Sundararajan V; Ratnam D; Levy MT; Lubel JS; Nicoll A; Strasser SI; Sievert W; Desmond PV; Ngu MC; Angus P; Sinclair M; Meredith C; Matthews G; Revill PA; Jackson K; Littlejohn M; Bowden D; Locarnini SA; Visvanathan K; Thompson A, 2022, 'Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels', Alimentary Pharmacology and Therapeutics, 56, pp. 310 - 320, http://dx.doi.org/10.1111/apt.16968
2022
Mylonakis E; Lutaakome J; Jain MK; Rogers AJ; Moltó J; Benet S; Mourad A; Files DC; Mugerwa H; Kityo C; Kiweewa F; Nalubega MG; Kitonsa J; Nabenkema E; Murray DD; Braun D; Kamel D; Higgs ES; Hatlen TJ; Kan VL; Sanchez A; Tierney J; Denner E; Wentworth D; Babiker AG; Davey VJ; Gelijns AC; Matthews GV; Thompson BT; Lane HC; Neaton JD; Lundgren JD, 2022, 'Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO)', Med, 3, pp. 531 - 537, http://dx.doi.org/10.1016/j.medj.2022.07.003
2022
Marshall AD; Matthews GV, 2022, 'Simplifying hepatitis C care models: a crucial step towards hepatitis C elimination', The Lancet Gastroenterology and Hepatology, 7, pp. 1066 - 1068, http://dx.doi.org/10.1016/S2468-1253(22)00306-5
2022
Wheeler A; Valerio H; Cunningham EB; Martinello M; Barocas JA; Colledge-Frisby S; Treloar C; Amin J; Henderson C; Read P; Matthews GV; Dunlop AJ; Gorton C; Hayllar J; Alavi M; Murray C; Marks P; Silk D; Degenhardt L; Dore GJ; Grebely J, 2022, 'Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study', Drug and Alcohol Dependence, 237, http://dx.doi.org/10.1016/j.drugalcdep.2022.109543
2022
Shah SHBU; Alavi M; Hajarizadeh B; Matthews GV; Martinello M; Danta M; Amin J; Law MG; George J; Valerio H; Dore GJ, 2022, 'Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales', JHEP Reports, 4, http://dx.doi.org/10.1016/j.jhepr.2022.100552
2022
Catlett B; Starr M; Machalek DA; Danwilai T; Palmer M; Kelly A; Kaldor J; Dore GJ; Darley D; Matthews G; Cunningham PH, 2022, 'Evaluation of serological assays for SARS-CoV-2 antibody testing from dried blood spots collected from cohorts with prior SARS-CoV-2 infection: SARS-CoV-2 detection from dried blood spots', Journal of Clinical Virology Plus, 2, http://dx.doi.org/10.1016/j.jcvp.2022.100093
2022
Bartlett SR; Verich A; Carson J; Hosseini-Hooshyar S; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Martinez M; Marks P; Dore GJ; Matthews GV; Applegate T; Martinello M; Hosseini Hooshyar S, 2022, 'Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort', Health Science Reports, 5, http://dx.doi.org/10.1002/hsr2.719
2022
Papot E; Jacoby S; Arlinda D; Avihingsanon A; Azwa I; Borok M; Brown D; Cisse M; Dao S; Eriobu N; Kaplan R; Karyana M; Kumarasamy N; Losso MH; Matthews GV; Perelis L; Perez-Casas C; Ruxrungtham K; Watkins M; Lane HC; Kelleher A; Law M; Polizzotto M, 2022, 'Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT', HIV Research & Clinical Practice, 23, pp. 37 - 46, http://dx.doi.org/10.1080/25787489.2022.2103572
2022
Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Matthews GV; Dore GJ; Post J; Batey R; Smart J; Dawson O; Hill S; Douglas M; Montebello M; Collie P; Hallinan R; Snelgar G; Baker D; Galhenage S; Soo TM; Bopage R; Faros J; Cooper L; Nelson R; Shaw D; Wilson M; Pratt W; Hinton S; Wade A; Van Gessel H; Davidson L; Dibdin M; Lucas M; Ahmad R; Smith D; Tan K; Roder C; Harney B; Holdaway S; Walsh J; Fox P; Mousavi R; Lam W; Dahal RP; Habel P; Gilliver R; Silins E; Ackerman J; Deacon R; Hall E; Everson A; Stewart J; Milner M; Ferguson C; Tate-Baker J; Bradshaw J; Duncan G; Baluran G; Watson B; Hey C; Hickey R; Orme C; Miczkova S, 2022, 'Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH-C cohort', Journal of Viral Hepatitis, 29, pp. 661 - 676, http://dx.doi.org/10.1111/jvh.13705
2022
Harney BL; Sacks-Davis R; Van Santen DK; Traeger M; Wilkinson AL; Asselin J; El-Hayek C; Fairley CK; Roth N; Bloch M; Matthews G; Donovan B; Guy R; Stoové M; Hellard ME; Doyle JS; Bastian L; Bateson D; Bowden S; Boyd M; Callander D; Carter A; Cogle A; Costello J; Dimech W; Dittmer J; Ellard J; Franklin L; Kim J; Mcgill S; Nolan D; Patel P; Pendle S; Polkinghorne V; Nguyen L; Nguyen T; O'connor C; Reed P; Ryder N; Selvey C; Vickers T; Walker M; Watchirs-Smith L; West M, 2022, 'The Incidence of Hepatitis C Among Gay, Bisexual, and Other Men Who Have Sex With Men in Australia, 2009-2019', Clinical Infectious Diseases, 74, pp. 1804 - 1811, http://dx.doi.org/10.1093/cid/ciab720
2022
Yee J; Carson JM; Hajarizadeh B; Hanson J; O’Beirne J; Iser D; Read P; Balcomb A; Doyle JS; Davies J; Martinello M; Marks P; Dore GJ; Matthews GV; Hanson J; Marks P; Byrne M; Post J; Batey R; Smart J; Dawson O; Hill S; Douglas M; Montebello M; Collie P; Hallinan R; Snelgar G; Baker D; Galhenage S; Soo TM; Bopage R; Faros J; Cooper L; Nelson R; Shaw D; Davies J; Wilson M; Pratt W; Hinton S; Wade A; Van Gessel H; Davidson L; Dibdin M; Lucas M; Ahmad R; Smith D; Tan K; Roder C; Harney B; Holdaway S; Walsh J; Fox P; Mousavi R; Lam W; Dahal RP; Habel P; Gilliver R; Silins E; Ackerman J; Deacon R; Hall E; Everson A; Milner M; Ferguson C; Tate-Baker J; Bradshaw J; Duncan G; Baluran G; Watson B; Hey C; Hickey R; Orme C; Miczkova S, 2022, 'High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study', Hepatology Communications, 6, pp. 496 - 512, http://dx.doi.org/10.1002/hep4.1826
2022
Adhikari A; Abayasingam A; Rodrigo C; Agapiou D; Pandzic E; Brasher NA; Fernando BSM; Keoshkerian E; Li H; Kim HN; Lord M; Popovic G; Rawlinson W; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson SC; Grubor-Bauk B; Lloyd AR; Martinello M; Bull RA; Tedla N; Kaldor J; Dore G; Sorrell T; Bartlett A; Lemberg D; Di Girolamo N; Byrne M; Hammoud M; Sultan R; Konecny P; Matthews G; Shek D; Holdaway S; Mitsa-Kos K; How-Chow D; Lagunday R; Robinson S; Terrill L; Joshi N; Li Y; Gill S; Sevehon A, 2022, 'Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection', Journal of Immunology, 209, pp. 1499 - 1512, http://dx.doi.org/10.4049/jimmunol.2200272
2022
Hosseini-Hooshyar S; Alavi M; Martinello M; Valerio H; Tillakeratne S; Matthews GV; Dore GJ, 2022, 'Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study', Journal of Viral Hepatitis, 29, pp. 271 - 279, http://dx.doi.org/10.1111/jvh.13658
2022
Harnpariphan W; Han WM; Supanun R; Ubolyam S; Sophonphan J; Ueaphongsukkit T; Gatechompol S; Tangkijvanich P; Thanprasertsuk S; Khwairakpam G; Ruxrungthan K; Phanuphak P; Matthews GV; Avihingsanon A, 2022, 'High Proportion of Blood-Borne and Sexually Transmitted Infections among People Deprived of Liberty in a Central Male Prison in Thailand: A Cross-Sectional Study 2018-2019', AIDS Research and Human Retroviruses, 38, pp. 370 - 377, http://dx.doi.org/10.1089/aid.2021.0134
2022
Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua NZ; Fierer DS; Chromy D; Rockstroh JK; Martin TCS; Ingiliz P; Hung CC; Dore GJ; Martinello M; Matthews GV, 2022, 'Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression', The Lancet HIV, 9, pp. e414 - e427, http://dx.doi.org/10.1016/S2352-3018(22)00077-7
2022
Krishnan A; Ellenberger K; Chansavath P; Kelleher A; Matthews G; Darley D; Holloway C, 2022, 'Myocardial Fibrosis Occurs in Non-Hospitalised Patients With Chronic Symptoms After COVID-19', Heart, Lung and Circulation, 31, pp. S169 - S170, http://dx.doi.org/10.1016/j.hlc.2022.06.267
2022
He WQ; Matthews GV; Liu B, 2022, 'Characteristics Associated with Monitoring and Treatment of Chronic Hepatitis B in a Large Cohort of Australian Adults', Digestive Diseases and Sciences, 67, pp. 2600 - 2607, http://dx.doi.org/10.1007/s10620-021-07008-z
2022
Marshall AD; Martinello M; Treloar C; Matthews GV, 2022, 'Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission: The CEASE qualitative study', International Journal of Drug Policy, 109, http://dx.doi.org/10.1016/j.drugpo.2022.103828
2022
Douin DJ; Siegel L; Grandits G; Phillips A; Aggarwal NR; Baker J; Brown SM; Chang CC; Goodman AL; Grund B; Higgs ES; Hough CL; Murray DD; Paredes R; Parmar M; Pett S; Polizzotto MN; Sandkovsky U; Self WH; Young BE; Babiker AG; Davey VJ; Kan V; Gelijns AC; Matthews G; Thompson BT; Lane HC; Neaton JD; Lundgren JD; Ginde AA; Meintjes GA; Armstrong W; Glidden D; Maldonado Y; Murray BE; Ray SC; Rolla VC; Saloojee H; Tsiatis AA; Volberding PA; Kimmelman J; Hunsberger S, 2022, 'Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery', American Journal of Respiratory and Critical Care Medicine, 206, pp. 730 - 739, http://dx.doi.org/10.1164/rccm.202112-2836OC
2022
Rogers AJ; Wentworth D; Phillips A; Shaw-Saliba K; Dewar RL; Aggarwal NR; Babiker AG; Chang W; Dharan NJ; Davey VJ; Higgs ES; Gerry N; Ginde AA; Hayanga JWA; Highbarger H; Highbarger JL; Jain MK; Kan V; Kim K; Lallemand P; Leshnower BG; Lutaakome JK; Matthews G; Mourad A; Mylonakis E; Natarajan V; Padilla ML; Pandit LM; Paredes R; Pett S; Ramachandruni S; Rehman MT; Sherman BT; Files DC; Brown SM; Matthay MA; Thompson BT; Neaton JD; Lane HC; Lundgren JD, 2022, 'The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19', Annals of Internal Medicine, 175, pp. 1401 - 1410, http://dx.doi.org/10.7326/M22-0924
2022
Mylonakis E, 2022, 'Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 A Randomized Controlled Trial', Annals of Internal Medicine, 175, pp. 1266 - 1274, http://dx.doi.org/10.7326/M22-1503
2022
Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks ML; Law H; Danwilai T; Starr M; Munier CML; Christ D; Singh M; Croucher PI; Brilot-Turville F; Turville S; Phan TG; Dore GJ; Darley D; Cunningham P; Matthews GV; Kelleher AD; Zaunders JJ, 2022, 'High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells', Frontiers in Immunology, 13, http://dx.doi.org/10.3389/fimmu.2022.1032911
2022
Holland TL; Ginde AA; Paredes R; Murray TA; Engen N; Grandits G; Vekstein A; Ivey N; Mourad A; Sandkovsky U; Gottlieb RL; Berhe M; Jain MK; Marines-Price R; Agbor Agbor BT; Mateu L; España-Cueto S; Lladós G; Mylonakis E; Rogers R; Shehadeh F; Filbin MR; Hibbert KA; Kim K; Tran T; Morris PE; Cassity EP; Trautner B; Pandit LM; Knowlton KU; Leither L; Matthay MA; Rogers AJ; Drake W; Jones B; Poulakou G; Syrigos KN; Fernández-Cruz E; Natale MD; Almasri E; Balerdi-Sarasola L; Bhagani SR; Boyle KL; Casey JD; Chen P; Douin DJ; Files DC; Günthard HF; Hite RD; Hyzy RC; Khan A; Kibirige M; Kidega R; Kiweewa F; Jensen JU; Leshnower BG; Lutaakome JK; Manian P; Menon V; Morales-Rull JL; O'Mahony DS; Overcash JS; Ramachandruni S; Steingrub JS; Taha HS; Waters M; Young BE; Phillips AN; Murray DD; Jensen TO; Padilla ML; Sahner D; Shaw-Saliba K; Dewar RL; Teitelbaum M; Natarajan V; Rehman MT; Pett S; Hudson F; Touloumi G; Brown SM; Self WH; Chang CC; Sánchez A; Weintrob AC; Hatlen T; Grund B; Sharma S; Reilly CS; Garbes P; Esser MT; Templeton A; Babiker AG; Davey VJ; Gelijns AC; Higgs ES; Kan V; Matthews G; Thompson BT; Neaton JD, 2022, 'Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial', The Lancet Respiratory Medicine, 10, pp. 972 - 984, http://dx.doi.org/10.1016/S2213-2600(22)00215-6
2022
Phetsouphanh C; Darley D; Wilson D; Howe A; Ling Munier M; Patel S; Juno J; Burrell L; Kent S; Dore G; Kelleher A; Matthews G, 2021, 'Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection', , http://dx.doi.org/10.1101/2021.06.01.21257759
2021
Jin F; Dore GJ; Matthews G; Luhmann N; Macdonald V; Bajis S; Baggaley R; Mathers B; Verster A; Grulich AE, 2021, 'Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 6, pp. 39 - 56, http://dx.doi.org/10.1016/S2468-1253(20)30303-4
2021
Stafford F; Dore GJ; Clackett S; Martinello M; Matthews GV; Grebely J; Balcomb AC; Hajarizadeh B, 2021, 'Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program', Medical Journal of Australia, 215, pp. 332 - 333, http://dx.doi.org/10.5694/mja2.51204
2021
Bastard P; Gervais A; Voyer TL; Rosain J; Philippot Q; Manry J; Michailidis E; Hoffmann HH; Eto S; Garcia-Prat M; Bizien L; Parra-Martínez A; Yang R; Haljasmägi L; Migaud M; Särekannu K; Maslovskaja J; De Prost N; Tandjaoui-Lambiotte Y; Luyt CE; Amador-Borrero B; Gaudet A; Poissy J; Morel P; Richard P; Cognasse F; Troya J; Trouillet-Assant S; Belot A; Saker K; Garçon P; Rivière JG; Lagier JC; Gentile S; Rosen LB; Shaw E; Morio T; Tanaka J; Dalmau D; Tharaux PL; Sene D; Stepanian A; Megarbane B; Triantafyllia V; Fekkar A; Heath JR; Franco JL; Anaya JM; Solé-Violán J; Imberti L; Biondi A; Bonfanti P; Castagnoli R; Delmonte OM; Zhang Y; Snow AL; Holland SM; Biggs CM; Moncada-Vélez M; Arias AA; Lorenzo L; Boucherit S; Coulibaly B; Anglicheau D; Planas AM; Haerynck F; Duvlis S; Nussbaum RL; Ozcelik T; Keles S; Bousfiha AA; El Bakkouri J; Ramirez-Santana C; Paul S; Pan-Hammarström Q; Hammarström L; Dupont A; Kurolap A; Metz CN; Aiuti A; Casari G; Lampasona V; Ciceri F; Barreiros LA; Dominguez-Garrido E; Vidigal M; Zatz M; Van De Beek D; Sahanic S; Tancevski I; Stepanovskyy Y; Boyarchuk O; Nukui Y; Tsumura M; Vidaur L; Tangye SG; Burrel S; Duffy D; Quintana-Murci L; Klocperk A, 2021, 'Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths', Science Immunology, 6, http://dx.doi.org/10.1126/sciimmunol.abl4340
2021
Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Dore GJ; Matthews GV, 2021, 'Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103422
2021
Darley DR; Dore GJ; Byrne A; Plit M; Brew BJ; Kelleher A; Matthews GV, 2021, 'Limited recovery from post-acute sequelae of SARS-CoV-2 (PASC) at eight months in a prospective cohort', , http://dx.doi.org/10.1101/2021.03.29.21254211
2021
Darley DR; Dore GJ; Byrne AL; Plit ML; Brew BJ; Kelleher A; Matthews GV, 2021, 'Limited recovery from post-acute sequelae of sars-cov-2 at 8 months in a prospective cohort', ERJ Open Research, 7, http://dx.doi.org/10.1183/23120541.00384-2021
2021
Liu B; Jayasundara D; Pye V; Dobbins T; Dore GJ; Matthews G; Kaldor J; Spokes P, 2021, 'Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia', The Lancet Regional Health - Western Pacific, 12, http://dx.doi.org/10.1016/j.lanwpc.2021.100193
2021
Tea F; Stella AO; Aggarwal A; Darley DR; Pilli D; Vitale D; Merheb V; Lee FXZ; Cunningham P; Walker GJ; Fichter C; Brown DA; Rawlinson WD; Isaacs SR; Mathivanan V; Hoffmann M; Pöhlman S; Mazigi O; Christ D; Rockett RJ; Sintchenko V; Hoad VC; Irving DO; Dore GJ; Gosbell IB; Kelleher AD; Matthews GV; Brilot F; Turville SG, 2021, 'SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants', PLoS Medicine, 18, http://dx.doi.org/10.1371/journal.pmed.1003656
2021
Matthews GV; Bhagani S; Van der Valk M; Rockstroh J; Feld JJ; Rauch A; Thurnheer C; Bruneau J; Kim A; Hellard M; Shaw D; Gane E; Nelson M; Ingiliz P; Applegate TL; Grebely J; Marks P; Martinello M; Petoumenos K; Dore GJ; Marks P; Feld J; Amjad S; Tu E; Tamaddoni M; Thurnheer MC; Gilleece Y; Fraser C; Moriggia A; Lutz T; Moon J; Read P; Ustianowski A; Cordes C; Sasadeusz J; Hull M; Braun D, 2021, 'Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection', Journal of Hepatology, 75, pp. 829 - 839, http://dx.doi.org/10.1016/j.jhep.2021.04.056
2021
Fulford TS; Van H; Gherardin NA; Zheng S; Ciula M; Drummer HE; Redmond S; Tan HX; Boo I; Center RJ; Li F; Grimley SL; Wines BD; Nguyen THO; Mordant FL; Ellenberg P; Rowntree LC; Kedzierski L; Cheng AC; Doolan DL; Matthews G; Bond K; Hogarth PM; McQuilten Z; Subbarao K; Kedzierska K; Juno JA; Wheatley AK; Kent SJ; Williamson DA; Purcell DFJ; Anderson DA; Godfrey DI, 2021, 'A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2', EBioMedicine, 74, http://dx.doi.org/10.1016/j.ebiom.2021.103729
2021
Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J, 2021, 'Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection among People Who Inject Drugs', Clinical Infectious Diseases, 72, pp. 1392 - 1400, http://dx.doi.org/10.1093/cid/ciaa253
2021
Valerio H; Alavi M; Law M; Tillakeratne S; Amin J; Janjua NZ; Krajden M; George J; Matthews GV; Hajarizadeh B; Degenhardt L; Grebely J; Dore GJ, 2021, 'High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia', Journal of Hepatology, 74, pp. 293 - 302, http://dx.doi.org/10.1016/j.jhep.2020.08.038
2021
Darley D; Matthews G; Dore G; Wilhelm K; Plit M; Stone E; Byrne A; Tonga K; Andresen D; Kelleher A; Cysique L; Cunningham P; Brew B, 2021, 'Persistent symptoms up to four months after community and hospital- managed SARS- CoV- 2 infection', Medical Journal of Australia, http://dx.doi.org/10.5694/mja2.50963
2021
Doyle JS; Van Santen DK; Iser D; Sasadeusz J; O'Reilly M; Harney B; Traeger MW; Roney J; Cutts JC; Bowring AL; Winter R; Medland N; Fairley CK; Moore R; Tee BK; Asselin J; El-Hayek C; Hoy JF; Matthews GV; Prins M; Stoové MA; Hellard ME, 2021, 'Microelimination of Hepatitis C among People with Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial', Clinical Infectious Diseases, 73, pp. E2164 - E2172, http://dx.doi.org/10.1093/cid/ciaa1500
2021
Marriott D; Beresford R; Mirdad F; Stark D; Glanville A; Chapman S; Harkness J; Dore GJ; Andresen D; Matthews GV, 2021, 'Concomitant Marked Decline in Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Other Respiratory Viruses among Symptomatic Patients Following Public Health Interventions in Australia: Data from St Vincent's Hospital and Associated Screening Clinics, Sydney, NSW', Clinical Infectious Diseases, 72, pp. E649 - E651, http://dx.doi.org/10.1093/cid/ciaa1256
2021
Valerio H; Alavi M; Law M; McManus H; Tillakeratne S; Bajis S; Martinello M; Matthews GV; Amin J; Janjua NZ; Krajden M; George J; Degenhardt L; Grebely J; Dore GJ, 2021, 'Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study', Clinical Infectious Diseases, 73, pp. 2037 - 2044, http://dx.doi.org/10.1093/cid/ciab526
2021
Ohata PJ; Su Lwin HM; Han WM; Khwairakpam G; Tangkijvanich P; Matthews GV; Avihingsanon A, 2021, 'Elimination of hepatitis C among HIV-positive population in Asia: Old and new challenges', Future Virology, 16, pp. 407 - 417, http://dx.doi.org/10.2217/fvl-2021-0015
2021
Acheson LS; Siefried KJ; Clifford B; Murray E; Steele M; Clague L; Malone V; Roberts DM; Ferguson LJ; Matthews GV; Ezard N, 2021, 'One-third of people who inject drugs are at risk of incomplete treatment for Staphylococcus aureus bacteraemia: a retrospective medical record review', International Journal of Infectious Diseases, 112, pp. 63 - 65, http://dx.doi.org/10.1016/j.ijid.2021.09.012
2021
Archer O; Perram J; Nadel J; Emmanuel S; Matthews G; Beresford R; Holloway CJ, 2021, 'Patients Living with HIV and Coronary Disease: Are we Using Appropriate Anti platelets as Part of Dual Antiplatelet Therapy?', Cardiology & Vascular Research, 5, http://dx.doi.org/10.33425/2639-8486.1094
2021
Feld JJ; Matthews GV, 2021, 'Don't Wait: The Benefits of Early Diagnosis in Perinatal Hepatitis C Virus Transmission', Clinical Infectious Diseases, 73, pp. E3347 - E3348, http://dx.doi.org/10.1093/cid/ciaa942
2021
Matthews G, 2021, 'Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial', Clinical Infectious Diseases, http://dx.doi.org/10.1093/cid/ciaa1500
2021
Asano T; Boisson B; Onodi F; Matuozzo D; Moncada-Velez M; Renkilaraj MRLM; Zhang P; Meertens L; Bolze A; Materna M; Korniotis S; Gervais A; Talouarn E; Bigio B; Seeleuthner Y; Bilguvar K; Zhang Y; Neehus AL; Ogishi M; Pelham SJ; Le Voyer T; Rosain J; Philippot Q; Soler-Palacín P; Colobran R; Martin-Nalda A; Rivière JG; Tandjaoui-Lambiotte Y; Chaïbi K; Shahrooei M; Darazam IA; Olyaei NA; Mansouri D; Hatipoğlu N; Palabiyik F; Novelli G; Novelli A; Casari G; Aiuti A; Carrera P; Bondesan S; Barzaghi F; Rovere-Querini P; Tresoldi C; Franco JL; Rojas J; Reyes LF; Bustos IG; Arias AA; Morelle G; Kyheng C; Troya J; Planas-Serra L; Schlüter A; Gut M; Pujol A; Allende LM; Rodriguez-Gallego C; Flores C; Cabrera-Marante O; Pleguezuelo DE; de Diego RP; Keles S; Aytekin G; Akcan OM; Bryceson YT; Bergman P; Brodin P; Smole D; Smith CIE; Norlin AC; Campbell TM; Covill LE; Hammarström L; Pan-Hammarström Q; Abolhassani H; Mane S; Marr N; Ata M; Al Ali F; Khan T; Spaan AN; Dalgard CL; Bonfanti P; Biondi A; Tubiana S; Burdet C; Nussbaum R; Kahn-Kirby A; Snow AL; Bustamante J; Puel A; Boisson-Dupuis S; Zhang SY; Béziat V; Lifton RP; Bastard P; Notarangelo LD; Abel L; Su HC, 2021, 'X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19', Science Immunology, 6, http://dx.doi.org/10.1126/sciimmunol.abl4348
2021
Denholm JT; Davis J; Paterson D; Roberts J; Morpeth S; Snelling T; Zentner D; Rees M; O'Sullivan M; Price D; Bowen A; Tong SYC; Anderson S; McQuilton Z; Venkatesh B; Hammond N; Jha V; Burston VJ; McMahon J; Charles P; Commons R; O'Brien D; Mahoney A; Sheffield D; Lim LL; Gardiner B; Schulz T; Torresi J; Chean R; Sasadeusz J; Rogers B; Aboltins C; Singh K; Yong M; Lister D; Visvanathan K; Molton J; Tai A; Chalmers R; Martinello M; Wilson P; Gray T; Coghill S; Foo H; Sud A; Williams J; Lwin N; Post J; Van Haal S; Sullivan R; Matthews G; Kwan BCH; Slack A; Shum O; Cochrane B; Dotel R; Gilbey T; Mina M; Su Y; Trethewy C; Hudson B; Chatterji A; Mostert C; New D; Raby E; Hui S; Robinson O; Hart J; Tan SJ; Arellano A; Chambers J; Davis J; Rafiei N; Smith S; Sehu M; Da Silva J; Griffin P; Henderson A; Chaw K; Choong K; Burke A; Heather C; Senanayake S; Boyd M; Rowe E; Anagnostou M; Trad A; Ratcliff A; Dummer J; Bhally H; Giola M; Grimwade K; Chang CLL; Verrall A; Hogg S; Restropo D; Maze M; Ritchie S; Gedye C; Chang J, 2020, 'The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial', Trials, 21, http://dx.doi.org/10.1186/s13063-020-04576-9
2020
Vogel JP; Tendal B; Giles M; Whitehead C; Burton W; Chakraborty S; Cheyne S; Downton T; Fraile Navarro D; Gleeson G; Gordon A; Hunt J; Kitschke J; McDonald S; McDonnell N; Middleton P; Millard T; Murano M; Oats J; Tate R; White H; Elliott J; Roach V; Homer CSE; McGowan S; Ballenden N; Barrett TL; Beavis V; Saunders JB; Buchanan T; Buchanan-Grey M; Casey D; Cowie M; Doyle J; Frydenberg M; Gnjidic D; Green S; Greenland R; Griffin K; Groombridge S; Hardy L; Hodak A; Holley A; Jovanovska V; Knight S; Michaels K; Morley P; Morphet J; Nou S; Russo P; Sarson M; Young A; Norris S; Morris-Donovan B; Gurry S; Hudson E; Hurley S; Primmer D; Timms S; Whicker S; Mukherjee S; Agostino J; Booth K; Burr L; Byers L; Cameron P; Cooper M; Cheng A; Fowler P; Glanville A; Leder K; McGloughlin S; McMullan B; McPhee E; Mitchell B; Morgan M; Myles P; O’Donnell C; Parr M; Phillips J; Randall R; Varndell W; Whyte I; William L; Brightwell R; Condon L; Deshpande A; Ehm A; Ferrie M; Muller J; Pullin L; Robinson E; Witt A; Larkins S; Morgan M; Taylor G; Agostino J; Burgess P; Agar M; Peiris D; Pearson S; Matthews G; McCarthy S, 2020, 'Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce', Australian and New Zealand Journal of Obstetrics and Gynaecology, 60, pp. 840 - 851, http://dx.doi.org/10.1111/ajo.13270
2020
Bastard P; Rosen LB; Zhang Q; Michailidis E; Hoffmann HH; Zhang Y; Dorgham K; Philippot Q; Rosain J; Béziat V; Manry J; Shaw E; Haljasmägi L; Peterson P; Lorenzo L; Bizien L; Trouillet-Assant S; Dobbs K; de Jesus AA; Belot A; Kallaste A; Catherinot E; Tandjaoui-Lambiotte Y; Le Pen J; Kerner G; Bigio B; Seeleuthner Y; Yang R; Bolze A; Spaan AN; Delmonte OM; Abers MS; Aiuti A; Casari G; Lampasona V; Piemonti L; Ciceri F; Bilguvar K; Lifton RP; Vasse M; Smadja DM; Migaud M; Hadjadj J; Terrier B; Duffy D; Quintana-Murci L; van de Beek D; Roussel L; Vinh DC; Tangye SG; Haerynck F; Dalmau D; Martinez-Picado J; Brodin P; Nussenzweig MC; Boisson-Dupuis S; Rodríguez-Gallego C; Vogt G; Mogensen TH; Oler AJ; Gu J; Burbelo PD; Cohen JI; Biondi A; Bettini LR; DÁngio M; Bonfanti P; Rossignol P; Mayaux J; Rieux-Laucat F; Husebye ES; Fusco F; Ursini MV; Imberti L; Sottini A; Paghera S; Quiros-Roldan E; Rossi C; Castagnoli R; Montagna D; Licari A; Marseglia GL; Duval X; Ghosn J; Tsang JS; Goldbach-Mansky R; Kisand K; Lionakis MS; Puel A; Zhang SY; Holland SM; Gorochov G; Jouanguy E; Rice CM; Cobat A; Notarangelo LD; Abel L; Su HC; Casanova JL; Arias AA; Darley D; Matthews G, 2020, 'Autoantibodies against type I IFNs in patients with life-threatening COVID-19', Science, 370, pp. eabd4585, http://dx.doi.org/10.1126/science.abd4585
2020
Tea F; Stella AO; Aggarwal A; Darley DR; Pilli D; Vitale D; Merheb V; Lee FXZ; Cunningham P; Walker GJ; Brown DA; Rawlinson WD; Isaacs SR; Mathivanan V; Hoffman M; Pöhlmann S; Dwyer DE; Rockett R; Sintchenko V; Hoad VC; Irving DO; Dore GJ; Gosbell IB; Kelleher AD; Matthews GV; Brilot F; Turville SG, 2020, 'SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants', , http://dx.doi.org/10.1101/2020.12.19.20248567
2020
Artenie AA; Cunningham EB; Dore GJ; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Lacombe K; Stedman C; Litwin AH; Marks P; Matthews GV; Quiene S; Erratt A; Bruneau J; Grebely J, 2020, 'Patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis c virus treatment with directacting antiviral therapies: An international study', Clinical Infectious Diseases, 70, pp. 2369 - 2376, http://dx.doi.org/10.1093/cid/ciz633
2020
Zhang Q; Liu Z; Moncada-Velez M; Chen J; Ogishi M; Bigio B; Yang R; Arias AA; Zhou Q; Han JE; Ugurbil AC; Zhang P; Rapaport F; Li J; Spaan AN; Boisson B; Boisson-Dupuis S; Bustamante J; Puel A; Ciancanelli MJ; Zhang SY; Béziat V; Jouanguy E; Abel L; Cobat A; Casanova JL; Bastard P; Korol C; Rosain J; Philippot Q; Chbihi M; Lorenzo L; Bizien L; Neehus AL; Kerner G; Seeleuthner Y; Manry J; Le Voyer T; Le Pen J; Schneider WM; Razooky BS; Hoffmann HH; Michailidis E; Rice CM; Sabli IKD; Hodeib S; Sancho-Shimizu V; Bilguvar K; Ye J; Maniatis T; Bolze A; Zhang Y; Notarangelo LD; Su HC; Onodi F; Korniotis S; Karpf L; Soumelis V; Bonnet-Madin L; Amara A; Dorgham K; Gorochov G; Smith N; Duffy D; Moens L; Meyts I; Meade P; Darley D; Tangye S; Matthews G, 2020, 'Inborn errors of type I IFN immunity in patients with life-threatening COVID-19', Science, 370, pp. eabd4570, http://dx.doi.org/10.1126/science.abd4570
2020
Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E, 2020, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial', Journal of Hepatology, 72, pp. 431 - 440, http://dx.doi.org/10.1016/j.jhep.2019.10.010
2020
Boesecke C; Boyd A; Rauch A; Lacombe K; Rodger A; Pharris A; Pozniak A; Rijnders B; Smit C; Smith C; Hoornenborg E; Wedemeyer H; Schinkel J; Nerlander L; Duffell E; Noori T; Berenguer J; Peters L; Cotte L; Salazar-Vizcaya L; Puoti M; Parczewski M; Martin N; Ingiliz P; Zandkuijl P; Dressler S; Naggie S; van de Laar T; Reiberger T; Matthews G; Bhagani S; Prins M; Rockstroh JK, 2020, 'Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases Consensus panel (vol 34, pg 1699, 2020)', AIDS, 34, pp. 2161 - 2163, http://dx.doi.org/10.1097/01.aids.0000721220.20643.93
2020
Grebely J; Read P; Cunningham EB; Weltman M; Matthews GV; Dunlop A; Montebello M; Martinello M; Gilliver R; Marks P; Applegate TL; Dore GJ, 2020, 'Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial', Health Science Reports, 3, http://dx.doi.org/10.1002/hsr2.151
2020
Iranpour N; Dore GJ; Martinello M; Matthews GV; Grebely J; Hajarizadeh B, 2020, 'Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: A retrospective cohort study', Sexual Health, 17, pp. 223 - 230, http://dx.doi.org/10.1071/SH19101
2020
Bradshaw D; Vasylyeva TI; Davis C; Pybus OG; Thézé J; Thomson EC; Martinello M; Matthews GV; Burholt R; Gilleece Y; Cooke GS; Page EE; Waters L; Nelson M, 2020, 'Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England', Journal of Viral Hepatitis, 27, pp. 721 - 730, http://dx.doi.org/10.1111/jvh.13286
2020
Hall S; Burns G; Levy M; Lubel J; Nicoll A; Matthews G; Desmond P; Sievert W; Bowden S; Locarnini S; Holmes J; Visvanathan K; Thompson A, 2020, 'A prospective study of nucleot(s)ide analogue discontinuation in non-cirrhotic HBeAg-negative chronic hepatitis B patients: interim analysis at week 48 demonstrates profound reductions of HBsAg associated with ALT flare', Journal of Hepatology, 73, pp. S69 - S70, http://dx.doi.org/10.1016/s0168-8278(20)30674-7
2020
Valerio H; Alavi M; Matthews G; Law M; McManus H; Amin J; Janjua N; Krajden M; Tillakeratne S; Gleeson V; George J; Degenhardt L; Grebely J; Dore G, 2020, 'Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study', JOURNAL OF HEPATOLOGY, 73, pp. S807 - S808, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587002392&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2020
Dore GJ; Danta M; Matthews GV, 2020, 'Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding', The Lancet Gastroenterology and Hepatology, 5, pp. 1028 - 1029, http://dx.doi.org/10.1016/S2468-1253(20)30270-3
2020
Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews GV, 2020, 'Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection', Hepatology, 72, pp. 7 - 18, http://dx.doi.org/10.1002/hep.31003
2020
Audsley J; Avihingsanon A; Littlejohn M; Bowden S; Matthews GV; Fairley CK; Lewin SR; Sasadeusz J, 2020, 'Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?', Journal of Acquired Immune Deficiency Syndromes, 84, pp. 527 - 533, http://dx.doi.org/10.1097/QAI.0000000000002386
2020
Cunningham EB; Hajarizadeh B; Amin J; Litwin AH; Gane E; Cooper C; Lacombe K; Hellard M; Read P; Powis J; Dalgard O; Bruneau J; Matthews GV; Feld JJ; Dillon JF; Shaw D; Bruggmann P; Conway B; Fraser C; Marks P; Dore GJ; Grebely J, 2020, 'Adherence to once-daily and twice-daily direct-acting antiviral therapy for Hepatitis C infection among people with recent injection drug use or current opioid agonist therapy', Clinical Infectious Diseases, 71, pp. E115 - E124, http://dx.doi.org/10.1093/cid/ciz1089
2020
Boettiger DC; Salazar-Vizcaya L; Dore GJ; Gray RT; Law MG; Callander D; Lea T; Rauch A; Matthews GV, 2020, 'Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 among Human Immunodeficiency Virus-positive Gay and Bisexual Men?', Clinical Infectious Diseases, 70, pp. 106 - 113, http://dx.doi.org/10.1093/cid/ciz164
2020
Dore GJ; Matthews GV, 2020, 'Universal screening for hepatitis C virus infection should be linked to universal treatment access', Nature Reviews Gastroenterology and Hepatology, 17, pp. 321 - 322, http://dx.doi.org/10.1038/s41575-020-0306-8
2020
Gorstein E; Martinello M; Churkin A; Dasgupta S; Walsh K; Applegate TL; Yardeni D; Etzion O; Uprichard SL; Barash D; Cotler SJ; Matthews GV; Dahari H, 2020, 'Modeling based response guided therapy in subjects with recent hepatitis C infection', Antiviral Research, 180, http://dx.doi.org/10.1016/j.antiviral.2020.104862
2020
Han WM; Colby DJ; Khlaiphuengsin A; Apornpong T; Kerr SJ; Ubolyam S; Kroon E; Phanuphak N; Vasan S; Matthews GV; Avihingsanon A; Ruxrungtham K; Phanuphak P; Tangkijvanich P, 2020, 'Large transmission cluster of acute hepatitis C identified among HIV-positive men who have sex with men in Bangkok, Thailand', Liver International, 40, pp. 2104 - 2109, http://dx.doi.org/10.1111/liv.14578
2020
Bajis S; Applegate TL; Grebely J; Matthews GV; Dore GJ, 2020, 'Novel hepatitic C virus (HCV) diagnosis and treatment delivery systems: Facilitating HCV elimination by thinking outside the clinic', Journal of Infectious Diseases, 222, pp. S758 - S772, http://dx.doi.org/10.1093/infdis/jiaa366
2020
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV, 2020, 'Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV', AIDS, 34, pp. 1347 - 1358, http://dx.doi.org/10.1097/QAD.0000000000002562
2020
Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, 2020, 'Moving towards Hepatitis C microelimination among people living with human immunodeficiency virus in Australia: The CEASE study', Clinical Infectious Diseases, 71, pp. 1502 - 1510, http://dx.doi.org/10.1093/cid/ciz985
2020
Dharan NJ; Neuhaus J; Rockstroh JK; Peters L; Gordin F; Arenas-Pinto A; Emerson C; Marks K; Hidalgo J; Sarmento-Castro R; Stephan C; Kumarasamy N; Emery S; Matthews GV, 2019, 'Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial', Hepatology, 69, pp. 1135 - 1150, http://dx.doi.org/10.1002/hep.30296
2019
Revill PA; Chisari FV; Block JM; Dandri M; Gehring AJ; Guo H; Hu J; Kramvis A; Lampertico P; Janssen HLA; Levrero M; Li W; Liang TJ; Lim SG; Lu F; Penicaud MC; Tavis JE; Thimme R; Arbuthnot P; Boonstra A; Chang KM; Chen PJ; Glebe D; Guidotti LG; Fellay J; Ferrari C; Jansen L; Lau DTY; Lok AS; Maini MK; Mason W; Matthews G; Paraskevis D; Petersen J; Rehermann B; Shin EC; Thompson A; van Bömmel F; Wang FS; Watashi K; Yang HC; Yuan Z; Yuen MF; Block T; Miller V; Protzer U; Bréchot C; Locarnini S; Peters MG; Schinazi RF; Zoulim F, 2019, 'A global scientific strategy to cure hepatitis B', The Lancet Gastroenterology and Hepatology, 4, pp. 545 - 558, http://dx.doi.org/10.1016/S2468-1253(19)30119-0
2019
Sharkawy RE; Bayoumi A; Metwally M; Mangia A; Berg T; Romero-Gomez M; Abate ML; Irving WL; Sheridan D; Dore GJ; Spengler U; Lampertico P; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Santoro R; Gallego-Durán R; Fischer J; Nattermann J; D’Ambrosio R; McLeod D; Powell E; latchoumanin O; Thabet K; Najim MAM; Douglas MW; Liddle C; Qiao L; George J; Eslam M; White R; Rojas A; Bassendine M; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Grebely J; Fragomeli V; Jonsson JR, 2019, 'A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms', Scientific Reports, 9, http://dx.doi.org/10.1038/s41598-018-35736-2
2019
Martinello M; Matthews GV, 2019, 'Management of acute HCV in the era of direct-acting antivirals: implications for elimination', The Lancet Gastroenterology and Hepatology, 4, pp. 256 - 257, http://dx.doi.org/10.1016/S2468-1253(19)30001-9
2019
Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Filep E; Petoumenos K; Marks P; Applegate T; Grebely J; Dore G; Nelson M; Matthews G, 2019, 'Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection', JOURNAL OF HEPATOLOGY, 70, pp. E231 - E231, http://dx.doi.org/10.1016/S0618-8278(19)30432-3
2019
Lockart I; Matthews GV; Danta M, 2019, 'Sexually transmitted hepatitis C infection: The evolving epidemic in HIV-positive and HIV-negative MSM', Current Opinion in Infectious Diseases, 32, pp. 31 - 37, http://dx.doi.org/10.1097/QCO.0000000000000515
2019
Dore G; Feld J; Thompson A; Martinello M; Muir A; Agarwal K; Mullhaupt B; Wedemeyer H; Lacombe K; Matthews G; Schultz M; Mercade GE; Kho D; Filep E; Petoumenos K; Marks P; Tatsch F; dos Santos AGP; Gane E, 2019, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study', JOURNAL OF HEPATOLOGY, 70, pp. E110 - E110, http://dx.doi.org/10.1016/S0618-8278(19)30196-3
2019
Bartlett SR; Applegate TL; Jacka BP; Martinello M; Lamoury FMJ; Danta M; Bradshaw D; Shaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2019, 'A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015', Journal of the International AIDS Society, 22, pp. e25222, http://dx.doi.org/10.1002/jia2.25222
2019
Olmstead AD; Montoya V; Chui CK; Dong W; Joy JB; Tai V; Poon AFY; Nguyen T; Brumme CJ; Martinello M; Matthews GV; Richard Harrigan P; Dore GJ; Applegate TL; Grebely J; Howe AYM, 2019, 'A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections', Infection, Genetics and Evolution, 69, pp. 76 - 84, http://dx.doi.org/10.1016/j.meegid.2019.01.016
2019
Hooshyar SH; Martinello M; Yee J; Bartlett S; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Marks P; Applegate T; Dore G; Matthews G, 2019, 'SAT-235-Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', Journal of Hepatology, 70, pp. e734 - e734, http://dx.doi.org/10.1016/s0618-8278(19)31468-9
2019
Santen DV; Hoy J; Agius P; Iser D; O'reilly M; Sasadeusz J; Stoove M; Roney J; Moore R; Bk T; Medland N; Fairley C; Gane E; Matthews G; Prins M; Hellard M; Doyle J, 2019, 'THU-098-Changes in liver stiffness measurements following DAA treatment among HIV/HCV-coinfected individuals: Does HIV contribute to liver disease after HCV cure?', Journal of Hepatology, 70, pp. e204 - e204, http://dx.doi.org/10.1016/s0618-8278(19)30379-2
2019
Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'SAT-232-Reinfection following successful HCV DAA therapy among people with recent injecting drug use', Journal of Hepatology, 70, pp. e732 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31465-3
2019
Layton C; Richmond J; Baker D; Owen L; Matthews G; Oliver-Landry E; Howell J; Doyle J, 2019, 'Eliminating hepatitis C: Part 2. Assessing your patient for antiviral treatment', Medicine Today, 20, pp. 24 - 32
2019
Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV, 2018, 'Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection', Journal of Viral Hepatitis, 25, pp. 1180 - 1188, http://dx.doi.org/10.1111/jvh.12917
2018
Sacks-Davis R; Doyle JS; Rauch A; Beguelin C; Pedrana AE; Matthews GV; Prins M; van der Valk M; Klein MB; Saeed S; Lacombe K; Chkhartishvili N; Altice FL; Hellard ME, 2018, 'Linkage and retention in hcv care for hiv-infected populations: Early data from the daa era', Journal of the International AIDS Society, 21, http://dx.doi.org/10.1002/jia2.25051
2018
Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial', The Lancet Gastroenterology and Hepatology, 3, pp. 153 - 161, http://dx.doi.org/10.1016/S2468-1253(17)30404-1
2018
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia', Journal of Viral Hepatitis, 25, pp. 640 - 648, http://dx.doi.org/10.1111/jvh.12852
2018
Martinello M; Dore GJ; Matthews GV; Grebely J, 2018, 'Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs', Infectious Disease Clinics of North America, 32, pp. 371 - 393, http://dx.doi.org/10.1016/j.idc.2018.02.003
2018
Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2018, 'Management of acute HCV infection in the era of direct-acting antiviral therapy', Nature Reviews Gastroenterology and Hepatology, 15, pp. 412 - 424, http://dx.doi.org/10.1038/s41575-018-0026-5
2018
Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ, 2018, 'Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy', International Journal of Drug Policy, 62, pp. 94 - 103, http://dx.doi.org/10.1016/j.drugpo.2018.10.004
2018
Cunningham EB; Amin J; Feld JJ; Bruneau J; Dalgard O; Powis J; Hellard M; Cooper C; Read P; Conway B; Dunlop AJ; Norton B; Litwin AH; Hajarizadeh B; Thurnheer MC; Dillon JF; Weltman M; Shaw D; Bruggmann P; Gane E; Fraser C; Marks P; Applegate TL; Quiene S; Siriragavan S; Matthews GV; Dore GJ; Grebely J, 2018, 'Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study', International Journal of Drug Policy, 62, pp. 14 - 23, http://dx.doi.org/10.1016/j.drugpo.2018.08.013
2018
Khaw C; Richardson D; Matthews G; Read T, 2018, 'Looking at the positives: Proactive management of STIs in people with HIV', AIDS Research and Therapy, 15, http://dx.doi.org/10.1186/s12981-018-0216-9
2018
Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV, 2018, 'Erratum: Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection (Open Forum Infect Diss (2016)3:2(ofw105) DOI: 10.1093/ofid/ofw105)', Open Forum Infectious Diseases, 5, http://dx.doi.org/10.1093/ofid/ofy033
2018
Jin F; Matthews GV; Grulich AE, 2017, 'Sexual transmission of hepatitis C virus among gay and bisexual men: A systematic review', Sexual Health, 14, pp. 28 - 41, http://dx.doi.org/10.1071/SH16141
2017
Bartlett SR; Wertheim JO; Bull RA; Matthews GV; Lamoury FMJ; Scheffler K; Hellard M; Maher L; Dore GJ; Lloyd AR; Applegate TL; Grebely J, 2017, 'A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies', Journal of Viral Hepatitis, 24, pp. 404 - 411, http://dx.doi.org/10.1111/jvh.12652
2017
Eslam M; McLeod D; Kelaeng KS; Mangia A; Berg T; Thabet K; Irving WL; Dore GJ; Sheridan D; Grønbæk H; Abate ML; Hartmann R; Bugianesi E; Spengler U; Rojas A; Booth DR; Weltman M; Mollison L; Cheng W; Riordan S; Mahajan H; Fischer J; Nattermann J; Douglas MW; Liddle C; Powell E; Romero-Gomez M; George J; Metwally M; White R; Gallego-Duran R; Leung R; Mahajan N; Bassendine M; Rahme A; Rosso C; Mezzabotta L; Malik B; Matthews G; Asimakopoulos A; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santoro R, 2017, 'IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis', Nature Genetics, 49, pp. 795 - 800, http://dx.doi.org/10.1038/ng.3836
2017
Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2017, 'HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs', Current HIV/AIDS Reports, 14, pp. 110 - 121, http://dx.doi.org/10.1007/s11904-017-0358-8
2017
Martinello M; Grebely J; Petoumenos K; Gane E; Hellard M; Shaw D; Sasadeusz J; Applegate TL; Dore GJ; Matthews GV, 2017, 'HCV reinfection incidence among individuals treated for recent infection', Journal of Viral Hepatitis, 24, pp. 359 - 370, http://dx.doi.org/10.1111/jvh.12666
2017
Durier N; Yunihastuti E; Ruxrungtham K; Kinh NV; Kamarulzaman A; Boettiger D; Widhani A; Avihingsanon A; Huy BV; Syed Omar SFB; Sanityoso A; Chittmittrapap S; Dung NTH; Pillai V; Suwan-Ampai T; Law M; Sohn AH; Matthews G; Han A, 2017, 'Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia', Journal of Viral Hepatitis, 24, pp. 187 - 196, http://dx.doi.org/10.1111/jvh.12630
2017
Boettiger DC; Law MG; Dore GJ; Guy R; Callander D; Donovan B; O'Connor CC; Fairley CK; Hellard M; Matthews G; Han A, 2017, 'Hepatitis C testing and re-testing among people attending sexual health services in Australia, and hepatitis C incidence among people with human immunodeficiency virus: Analysis of national sentinel surveillance data', BMC Infectious Diseases, 17, pp. 740, http://dx.doi.org/10.1186/s12879-017-2848-0
2017
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2017, 'Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014)', Hepatology Communications, 1, pp. 736 - 747, http://dx.doi.org/10.1002/hep4.1073
2017
Puhr R; Wright ST; Hoy JF; Templeton DJ; Durier N; Matthews GV; Russell D; Law MG, 2017, 'Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database', Sexual Health, 14, pp. 345 - 354, http://dx.doi.org/10.1071/SH16151
2017
Bartlett SR; Grebely J; Eltahla AA; Reeves JD; Howe AYM; Miller V; Ceccherini-Silberstein F; Bull RA; Douglas MW; Dore GJ; Harrington P; Lloyd AR; Jacka B; Matthews GV; Wang GP; Pawlotsky JM; Feld JJ; Schinkel J; Garcia F; Lennerstrand J; Applegate TL, 2017, 'Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review', Hepatology Communications, 1, pp. 379 - 390, http://dx.doi.org/10.1002/hep4.1050
2017
Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Filep E; Skurowski J; Lin L; Lamoury F; Bartlett S; Applegate T; Hellard M; Matthews GV, 2017, 'O7 Moving towards HCV elimination in HIV/HCV co- infection in Australia following universal access to interferon-free therapy', Journal of Virus Eradication, 3, pp. 3 - 3, http://dx.doi.org/10.1016/s2055-6640(20)30890-6
2017
Bartlett SR; Applegate T; Jacka B; Lamoury F; Bull R; Danta M; Bradshaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2017, 'P6 Phylogenetic clustering of recent hepatitis C virus infection between 2004 and 2015', Journal of Virus Eradication, 3, pp. 14 - 15, http://dx.doi.org/10.1016/s2055-6640(20)30747-0
2017
Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P, 2017, 'Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study', Hepatology International, 11, pp. 188 - 198, http://dx.doi.org/10.1007/s12072-017-9788-z
2017
Alavi M; Amin J; Grebely J; Law MG; Janjua NZ; Krajden M; Hajarizadeh B; George J; Matthews GV; Larney S; Degenhardt L; Dore GJ, 2017, 'O23 Characterisation of populations with hepatitis C to improve access to antiviral therapy programs: a population-based linkage study', Journal of Virus Eradication, 3, pp. 9 - 9, http://dx.doi.org/10.1016/s2055-6640(20)30906-7
2017
Doyle JS; Bowring AL; Cutts J; Roney J; Iser DM; Sasadeusz J; O’Reilly M; Fairley C; Gane E; Hoy J; Matthews GV; Medland N; Moore R; Prins M; Stoové M; Tee BK; Hellard ME, 2017, 'O5 Hepatitis C elimination in HIV/HCV co-infection through HCV treatment in primary care is feasible and highly effective', Journal of Virus Eradication, 3, pp. 2 - 2, http://dx.doi.org/10.1016/s2055-6640(20)30888-8
2017
Martinello M; Grebely J; Matthews GV, 2017, 'Direct-acting antivirals for acute HCV: how short can we go?', The Lancet Gastroenterology and Hepatology, 2, pp. 316 - 318, http://dx.doi.org/10.1016/S2468-1253(17)30043-2
2017
Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', Journal of Virus Eradication, 3, pp. 5 - 5, http://dx.doi.org/10.1016/s2055-6640(20)30896-7
2017
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia', Journal of Virus Eradication, 3, pp. 19 - 19, http://dx.doi.org/10.1016/s2055-6640(20)30761-5
2017
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', Antiviral therapy, 21, pp. 465, http://dx.doi.org/10.3851/IMP3073
2016
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ; Han A, 2016, 'Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)', Journal of Hepatology, 65, pp. 1086 - 1093, http://dx.doi.org/10.1016/j.jhep.2016.08.010
2016
Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P; Dore GJ; Matthews GV; Cooper D, 2016, 'Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study', Hepatology, 64, pp. 1911 - 1921, http://dx.doi.org/10.1002/hep.28844
2016
Bartlett SR; Jacka B; Bull RA; Luciani F; Matthews GV; Lamoury FMJ; Hellard ME; Hajarizadeh B; Teutsch S; White B; Maher L; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection', Infection, Genetics and Evolution, 37, pp. 252 - 258, http://dx.doi.org/10.1016/j.meegid.2015.11.028
2016
Hajarizadeh B; Grebely J; Martinello M; Matthews GV; Lloyd AR; Dore GJ, 2016, 'Hepatitis C treatment as prevention: evidence, feasibility, and challenges', The Lancet Gastroenterology and Hepatology, 1, pp. 317 - 327, http://dx.doi.org/10.1016/S2468-1253(16)30075-9
2016
Hajarizadeh B; Lamoury FMJ; Feld JJ; Amin J; Keoshkerian E; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection', Virology Journal, 13, pp. 32, http://dx.doi.org/10.1186/s12985-016-0482-x
2016
Sheridan DA; Hajarizadeh B; Fenwick FI; Matthews GV; Applegate T; Douglas M; Neely D; Askew B; Dore GJ; Lloyd AR; George J; Bassendine MF; Grebely J, 2016, 'Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection', Liver International, 36, pp. 1774 - 1782, http://dx.doi.org/10.1111/liv.13176
2016
Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', ANTIVIRAL THERAPY, 21, pp. 127 - 132, http://dx.doi.org/10.3851/imp2984
2016
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', ANTIVIRAL THERAPY, 21, pp. 425 - 434, http://dx.doi.org/10.3851/IMP3035
2016
Doyle JS; Grebely J; Spelman T; Alavi M; Matthews GV; Thompson AJ; Dore GJ; Hellard ME; Kaldor J; Marks P; Lloyd A; Haber P; French R; White P; Rawlinson W; Day C; Van Beek I; McCaughan G; Madden A; Dolan K; Farrell G; Crofts N; Sievert W; Baker D, 2016, 'Quality of life and social functioning during treatment of recent hepatitis C infection: A multi-centre prospective cohort', PLoS ONE, 11, pp. e0150655, http://dx.doi.org/10.1371/journal.pone.0150655
2016
Eslam M; Mangia A; Berg T; Chan HLY; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MAM; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J; White R; Rojas A; Gallego-Duran R; Bassendine M; Wong VWS; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2016, 'Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes', Hepatology, 64, pp. 34 - 46, http://dx.doi.org/10.1002/hep.28475
2016
Thabet K; Asimakopoulos A; Shojaei M; Romero-Gomez M; Mangia A; Irving WL; Berg T; Dore GJ; Grønbæk H; Sheridan D; Abate ML; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Spengler U; Nattermann J; Wahid A; Rojas A; White R; Douglas MW; McLeod D; Powell E; Liddle C; Van Der Poorten D; George J; Eslam M; Gallego-Duran R; Applegate T; Bassendine M; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2016, 'MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C', Nature Communications, 7, pp. 12757, http://dx.doi.org/10.1038/ncomms12757
2016
Martinello M; Amin J; Matthews GV; Dore GJ, 2016, 'Prevalence and disease burden of HCV coinfection in HIV cohorts in the Asia pacific region: A systematic review and meta-analysis', AIDS Reviews, 18, pp. 69 - 80
2016
Audsley J; Robson C; Aitchison S; Matthews GV; Iser D; Sasadeusz J; Lewin SR, 2016, 'Liver fibrosis regression measured by transient elastography in human immunodeficiency virus (HIV)-hepatitis B virus (HBV)-coinfected individuals on long-term HBV-active combination antiretroviral therapy', Open Forum Infectious Diseases, 3, pp. ofw035, http://dx.doi.org/10.1093/ofid/ofw035
2016
Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV, 2016, 'Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection', Open Forum Infectious Diseases, 3, pp. ofw105, http://dx.doi.org/10.1093/ofid/ofw105
2016
Lamoury FMJ; Hajarizadeh B; Keoshkerian E; Feld JJ; Amin J; Teutsch S; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Applegate TL; Grebely J; Dolan K, 2016, 'HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection', BMC Infectious Diseases, 16, pp. 241, http://dx.doi.org/10.1186/s12879-016-1567-2
2016
Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J, 2016, 'Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity', AIDS, 30, pp. 1597 - 1606, http://dx.doi.org/10.1097/QAD.0000000000001080
2016
Chen Yi Mei SLG; Burchell J; Skinner N; Millen R; Matthews G; Hellard M; Dore GJ; Desmond PV; Sundararajan V; Thompson AJ; Visvanathan K; Sasadeusz J, 2016, 'Toll-like receptor expression and signaling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis c virus infection', Journal of Infectious Diseases, 214, pp. 739 - 747, http://dx.doi.org/10.1093/infdis/jiw235
2016
Bradshaw D; Raghwani J; Jacka B; Sacks-Davis R; Lamoury F; Down I; Prestage G; Applegate TL; Hellard M; Sasadeusz J; Dore GJ; Pybus OG; Matthews GV; Danta M, 2016, 'Venue-based networks may underpin HCV transmissions amongst HIV-infected gay and bisexual men', PLoS ONE, 11, pp. e0162002, http://dx.doi.org/10.1371/journal.pone.0162002
2016
Simpson JD; Matthews GV; Brighton TA; Joseph JE, 2016, 'Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist', Internal Medicine Journal, 46, pp. 1096 - 1099, http://dx.doi.org/10.1111/imj.13181
2016
Eslam M; Hashem AM; Leung R; Romero-Gomez M; Berg T; Dore GJ; Chan HLK; Irving WL; Sheridan D; Abate ML; Adams LA; Mangia A; Weltman M; Bugianesi E; Spengler U; Shaker O; Fischer J; Mollison L; Cheng W; Powell E; Nattermann J; Riordan S; McLeod D; Armstrong NJ; Douglas MW; Liddle C; Booth DR; George J; Ahlenstiel G; Ampuero J; Bassendine M; Wong VWS; Rosso C; White R; Mezzabotta L; Suppiah V; Michalk M; Malik B; Matthews G; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2015, 'Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease', Nature Communications, 6, pp. 6422, http://dx.doi.org/10.1038/ncomms7422
2015
Bradshaw D; Lamoury F; Catlett B; Applegate TL; McAllister J; Dore GJ; Matthews GV; Danta M, 2015, 'A comparison of seminal hepatitis C virus (HCV) RNA levels during recent and chronic HCV infection in HIV-infected and HIV-uninfected individuals', Journal of Infectious Diseases, 211, pp. 736 - 743, http://dx.doi.org/10.1093/infdis/jiu550
2015
Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews GV; Saag MS; Zamor PJ; Orkin C; Gress J; Klopfer S; Shaughnessy M; Wahl J; Nguyen BYT; Barr E; Platt HL; Robertson MN; Sulkowski M, 2015, 'Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial', The Lancet HIV, 2, pp. e319 - e327, http://dx.doi.org/10.1016/S2352-3018(15)00114-9
2015
Lamoury FMJ; Bartlett S; Jacka B; Hajarizadeh B; Grebely J; Matthews GV; Dore GJ; Applegate TL, 2015, 'Interferon λ 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types', Journal of Molecular Diagnostics, 17, pp. 583 - 589, http://dx.doi.org/10.1016/j.jmoldx.2015.05.003
2015
Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J; Marks P; Amin J; Doab A; Carroll T; Teutsch S; Li H; Oon A; Cameron B; Lloyd A; White P; Rawlinson W; Jacqueline Flynn ; Goy K; Nguyen O; von Bibra S; Ffrench R; McCaughan G; Madden A; Farrell G; Crofts N; Sievert W; Baker D; Jacka B; Pan Y; Shaw D; Sasadeusz J; Crawford D; Phung N; George J; Bloch M; Hughes B; Mollison L; Roberts S; Desmond P; Acraman B, 2015, 'Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C', International Journal of Drug Policy, 26, pp. 976 - 983, http://dx.doi.org/10.1016/j.drugpo.2015.05.003
2015
Applegate TL; Gaudieri S; Plauzolles A; Chopra A; Grebely J; Lucas M; Hellard M; Luciani F; Dore GJ; Matthews GV, 2015, 'Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C', Antiviral Therapy, 20, pp. 199 - 208, http://dx.doi.org/10.3851/IMP2821
2015
Matthews G; Neuhaus J; Bhagani S; Mehta S; Vlahakis E; Doroana M; Naggie S; Arenas-Pinto A; Peters L; Rockstroh J, 2015, 'Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: A substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial', HIV Medicine, 16, pp. 129 - 136, http://dx.doi.org/10.1111/hiv.12241
2015
Lamoury FMJ; Jacka B; Bartlett S; Bull RA; Wong A; Amin J; Schinkel J; Poon AF; Matthews GV; Grebely J; Dore GJ; Applegate TL, 2015, 'The influence of hepatitis C virus genetic region on phylogenetic clustering analysis', PLoS ONE, 10, pp. e0131437, http://dx.doi.org/10.1371/journal.pone.0131437
2015
Sacks-Davis R; Grebely J; Dore GJ; Osburn W; Cox AL; Rice TM; Spelman T; Bruneau J; Prins M; Kim AY; Mcgovern BH; Shoukry NH; Schinkel J; Allen TM; Morris M; Hajarizadeh B; Maher L; Lloyd AR; Page K; Hellard M; Matthews G, 2015, 'Hepatitis c virus reinfection and spontaneous clearance of reinfection - The InC3 study', Journal of Infectious Diseases, 212, pp. 1407 - 1419, http://dx.doi.org/10.1093/infdis/jiv220
2015
Doyle JS; Deterding K; Grebely J; Wedemeyer H; Sacks-Davis R; Spelman T; Matthews G; Rice TM; Morris MD; McGovern BH; Kim AY; Bruneau J; Lloyd AR; Page K; Manns MP; Hellard ME; Dore GJ; Maher L, 2015, 'Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort', Journal of Viral Hepatitis, 22, pp. 1020 - 1032, http://dx.doi.org/10.1111/jvh.12429
2015
Martinello M; Matthews GV, 2015, 'Enhancing the detection and management of acute hepatitis C virus infection', International Journal of Drug Policy, 26, pp. 899 - 910, http://dx.doi.org/10.1016/j.drugpo.2015.07.003
2015
Punyawudho B; Thammajaruk N; Thongpeang P; Matthews G; Lewin SR; Burger D; Ruxrungtham K; Avihingsanon A, 2015, 'Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients', International Journal of Clinical Pharmacology and Therapeutics, 53, pp. 947 - 954, http://dx.doi.org/10.5414/CP202386
2015
Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews G; Saag M; Zamor P; Orkin C; Gress J; Klopfer S; Platt H; Robertson M; Sulkowski M, 2015, 'C-EDGE CO-INFECTED: PHASE 3 STUDY OF GRAZOPREVIR/ELBASVIR IN PATIENTS WITH HCV/HIV', JOURNAL OF HEPATOLOGY, 62, pp. S675 - S675, http://dx.doi.org/10.1016/S0168-8278(15)31089-8
2015
Holmes JA; Matthews GV; Thompson AJ, 2015, 'Reply', Hepatology, 61, pp. 409, http://dx.doi.org/10.1002/hep.27255
2015
Achhra AC; Boyd MA; Law MG; Matthews GV; Kelleher AD; Cooper DA; Han A, 2014, 'Moving away from ritonavir, abacavir, tenofovir, and efavirenz (RATE) - Agents that concern prescribers and patients: A feasibility study and call for a trial', PLoS ONE, 9, pp. e99530, http://dx.doi.org/10.1371/journal.pone.0099530
2014
Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Regression of advanced fibrosis following virological response to anti-HCV therapy', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29, pp. 85 - 85
2014
Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Safety and efficacy of telaprevir and boceprevir in the "real world": an Australian experience', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29, pp. 85 - 86
2014
Holmes JA; Roberts SK; Ali RJ; Dore GJ; Sievert W; Mccaughan GW; Crawford DH; Cheng WS; Weltman MD; Bonanzinga S; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Matthews GV; Thompson AJ, 2014, 'ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response', Hepatology, 59, pp. 2152 - 2160, http://dx.doi.org/10.1002/hep.27022
2014
Avihingsanon A; Jitmitraparp S; Tangkijvanich P; Ramautarsing RA; Apornpong T; Jirajariyavej S; Putcharoen O; Treeprasertsuk S; Akkarathamrongsin S; Poovorawan Y; Matthews GV; Lange JM; Ruxrungtham K, 2014, 'Advanced liver fibrosis by transient elastography, Fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: Role of vitamin D levels', Journal of Gastroenterology and Hepatology (Australia), 29, pp. 1706 - 1714, http://dx.doi.org/10.1111/jgh.12613
2014
Hajarizadeh B; Grebely J; Applegate T; Matthews GV; Amin J; Petoumenos K; Hellard M; Rawlinson W; Lloyd A; Kaldor J; Dore GJ; Dolan K, 2014, 'Dynamics of HCV RNA Levels During Acute Hepatitis C Virus Infection', Journal of Medical Virology, 86, pp. 1722 - 1729, http://dx.doi.org/10.1002/jmv.24010
2014
Avihingsanon A; Apornpong T; Ramautarsing RA; Ubolyam S; Tangkijvanich P; Ananworanich J; Lange JMA; Matthews G; Lewin SR; Ruxrungtham K, 2014, 'Decline in serum 25 hydroxyvitamin D levels in HIV-HBV-coinfected patients after long-term antiretroviral therapy', Antiviral Therapy, 19, pp. 41 - 49, http://dx.doi.org/10.3851/IMP2673
2014
Giarda P; Avihingsanon A; Sasadeusz J; Audsley J; Marks P; Matthews G; Ruxrungtham K; Lewin SR; Crane M, 2014, 'CXCL-10, interleukin-12 and interleukin-21 are not immunological predictors of HBeAg seroconversion in HIV-1-HBV coinfection following HBV-active antiretroviral therapy', Antiviral Therapy, 19, pp. 429 - 433, http://dx.doi.org/10.3851/IMP2720
2014
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; Lauer G; Shoukry NH; Hahn J; Shiboski S; Rice TM; Alavi M; Bouchard R; Aneja J; Teutsch S; White B; Wells B; Zang G; Matthews G; Marks P; Yeung B; Prince LE; Roy E; Bates A; Enriquez J; Chow S; McCredie L; Aitken C; Doyle J; Spelman T; Evans J, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study', Journal of Clinical Virology, 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027
2014
Bradshaw D; Lamoury F; Catlett B; Mcallister J; Applegate T; Dore G; Matthews G; Danta M, 2014, 'Seminal HCV RNA level may mirror dynamics of plasma HCV RNA in HIV-infected men with acute HCV', HIV MEDICINE, 15, pp. 8 - 8
2014
Bradshaw D; Applegate T; Dore G; Hellard M; Sasadeusz J; Matthews G; Danta M, 2014, 'The majority of acute HCV infection in HIV-positive men who have sex with men (HIV plus MSM) is transmitted permucosally in the context of HIV serosorting in Australia', HIV MEDICINE, 15, pp. 137 - 137
2014
Crane M; Avihingsanon A; Rajasuriar R; Velayudham P; Iser D; Solomon A; Sebolao B; Tran A; Spelman T; Matthews G; Cameron P; Tangkijvanich P; Dore GJ; Ruxrungtham K; Lewin SR, 2014, 'Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy', Journal of Infectious Diseases, 210, pp. 745 - 751, http://dx.doi.org/10.1093/infdis/jiu119
2014
Grebely J; Feld JJ; Applegate T; Matthews GV; Hellard M; Sherker A; Petoumenos K; Zang G; Shaw I; Yeung B; George J; Teutsch S; Kaldor JM; Cherepanov V; Bruneau J; Shoukry NH; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection', Hepatology, 57, pp. 2124 - 2134, http://dx.doi.org/10.1002/hep.26263
2013
Matthews G; Seaberg E; Avihingsanon A; Bowden S; Dore GJ; Lewin SR; Sasadeusz JJ; Revill PA; Littlejohn M; Hoy J; Finlayson R; Ruxrungtham K; Saulynas M; Locarnini S; Thio C, 2013, 'Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus', Clinical Infectious Diseases, 56, pp. e87 - e94, http://dx.doi.org/10.1093/cid/cit002
2013
Suppiah V; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Nattermann J; Mueller T; Riordan S; Stewart GJ; George J; Booth DR; Ahlenstiel G; Michalk M; Malik B; McClure P; Smith S; Sheridan D; Snape E; Fragomeli V; Norris R; How-Chow D; Jonsson JR; Barrie H; Stelzer-Braid S; Fletcher S; Applegate T; Grebely J; Matthews G; Bharadwaj M; Smedile A, 2013, 'CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection', Genes and Immunity, 14, pp. 286 - 290, http://dx.doi.org/10.1038/gene.2013.15
2013
Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond RA; Bowden S; Lewin SR; Sasadeusz JJ; Littlejohn M; Locarnini SL; Ruxrungtham K; Dore GJ, 2013, 'Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals', PLoS One, 8, pp. e61297, http://dx.doi.org/10.1371/journal.pone.0061297
2013
Grebely J; Matthews GV; Lloyd AR; Dore GJ, 2013, 'Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: Feasibility and future requirements', Clinical Infectious Diseases, 57, pp. 1014 - 1020, http://dx.doi.org/10.1093/cid/cit377
2013
Holmes JA; Roberts SK; Sievert W; Dore GJ; Mccaughan M; Crawford DJ; Cheng W; Weltman M; Bonanzinga S; Visvanathan K; Desmond PV; Bowden DS; Matthews G; Thompson AJ, 2013, 'RBV pharmacokinetics explain the relationship between on-treatment anaemia and SVR, which is independent of ITPA genotype: analysis from the CHARIOT study', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28, pp. 171 - 172
2013
Feld JJ; Grebely J; Matthews GV; Applegate T; Hellard M; Sherker A; Cherepanov V; Petoumenos K; Yeung B; Kaldor JM; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection', PLoS ONE, 8, pp. e80003, http://dx.doi.org/10.1371/journal.pone.0080003
2013
Taylor LE; Swan T; Matthews GV, 2013, 'Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy', Clinical Infectious Diseases, 57, http://dx.doi.org/10.1093/cid/cit326
2013
Avihingsanon A; Matthews GV; Lewin SR; Marks P; Sasadeusz JJ; Cooper DA; Bowden S; Locarnini SA; Dore GJ; Ruxrungtham K, 2012, 'Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand', AIDS Research and Therapy, 9, pp. Article number 6, http://dx.doi.org/10.1186/1742-6405-9-6
2012
Holmes JA; Bonanzinga S; Roberts S; Sievert W; Dore G; Mccaughan G; Crawford DH; Cheng W; Weltman MD; Matthews G; Visvanathan K; Desmond P; Bowden DS; Thompson A, 2012, 'ITPA genotype strongly protects from ribavirin-induced haemolytic anaemia: analysis from the CHARIOT study', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 27, pp. 168 - 168
2012
Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Beek IV; Kaldor JM; Hellard M; Dore GJ; Haber PS; Alavi M; Van Beek I; Amin J; Dolan K; Rawlinson W; Flynn J; Marks P; Acraman B; Bloch M; Li H; Madden A; George J, 2012, 'Effect of pegylated interferon-a-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology, 27, pp. 957 - 965, http://dx.doi.org/10.1111/j.1440-1746.2011.07035.x
2012
Flynn J; Dore GJ; Matthews G; Hellard M; Yeung B; Rawlinson W; White PA; Kaldor JM; Lloyd AR; Ffrench RA; Dolan K, 2012, 'Impaired hepatitis C virus (HCV)-specific interferon-responses in individuals with HIV who acquire HCV infection: Correlation with CD4 + T-cell counts', Journal of Infectious Diseases, 206, pp. 1568 - 1576, http://dx.doi.org/10.1093/infdis/jis544
2012
Grebely J; Hellard M; Applegate TL; Petoumenos K; Yeung B; Feld J; Rawlinson WD; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews G; Dolan K, 2012, 'Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection', AIDS, 26, pp. 1653 - 1661, http://dx.doi.org/10.1097/QAD.0b013e3283553719
2012
Grebely J; Alavi M; Spelman T; Haber P; Day C; Matthews G; Van Beek I; Walsh N; Yeung B; Petoumenos K; Dolan K; Kaldor J; Dore G; Hellard M, 2012, 'IMPACT OF TREATMENT OF RECENTLY-ACQUIRED HEPATITIS C INFECTION ON INJECTING DRUG USE BEHAVIOURS', DRUG AND ALCOHOL REVIEW, 31, pp. 34 - 34
2012
Hellard M; Grebely J; Yeung B; Dore G; Marks P; Shaw D; Byrne M; Matthews G, 2012, 'EFFECTIVENESS OF RESPONSE-GUIDED THERAPY IN RECENT HEPATITIS C INFECTION: THE AUSTRALIAN TRIAL IN ACUTE HEPATITIS C', DRUG AND ALCOHOL REVIEW, 31, pp. 33 - 33
2012
Bradshaw D; Matthews G; Danta M, 2012, 'Sexually transmitted hepatitis C infection: The new epidemic in MSM?', Current Opinion in Infectious Diseases, 26, pp. 66 - 72, http://dx.doi.org/10.1097/QCO.0b013e32835c2120
2012
Cabuang LM; Shaw T; Littlejohn M; Colledge D; Sozzi V; Soppe S; Warner N; Thompson A; Preiss S; Lam N; Walsh R; Lewin SR; Thio CL; Matthews G; Locarnini SA; Revill PA, 2012, 'In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection', Journal of Medical Virology, 84, pp. 1166 - 1176, http://dx.doi.org/10.1002/jmv.23328
2012
Botes LP; Pett SL; Carr AD; Marriott D; Cooper DA; Matthews G; Carbone S; Kumaradevan N; Mchugh L; Hillman R, 2012, 'Anal cytological abnormalities are poor predictors of high-grade intraepithelial neoplasia amongst HIV-positive men who have sex with men.', Sexual Health, 10, pp. 9 - 17, http://dx.doi.org/10.1071/SH11135
2012
Botes LP; Jin F; Bourne CP; Pett SL; Marriott D; Carr AD; Cooper DA; Matthews G; Brew BJ; Hillman R, 2011, 'Participants' perspectives of self-collected anal cytological swabs', Sexual Health, 8, pp. 257 - 258, http://search.informit.com.au/documentSummary;dn=026957204834502;res=IELHEA
2011
Grebely J; Matthews G; Hellard M; Shaw D; van Beek I; Petoumenos K; Alavi M; Yeung B; Haber P; Lloyd AR; Kaldor JM; Dore GJ; Dolan K, 2011, 'Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users', Journal of Hepatology, 55, pp. 76 - 85, http://dx.doi.org/10.1016/j.jhep.2010.10.033
2011
Danta M, 2011, 'Acute Hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference', AIDS, 25, pp. 399 - 409
2011
Suppiah V; Gaudieri S; Armstrong N; O''connor K; Berg T; Weltman M; Abate M; Spengler U; Bassendine M; Dore G; Irving W; Powell E; Hellard M; Riordan S; Mathews G; Sheridan D; Natterman J; Smedile A; Muller T; Hammond E; Dunn D; Negro F; Bochud Y; Mallal S; Ahlenstiel G; Stewart G; George J; Booth D, 2011, 'IL28B, HLA-C and KIR variants additively and interactively predict response to therapy in chronic hepatitis C virus infection', PLOS Medicine, 8, pp. e1001092, http://dx.doi.org/10.1371/journal.pmed.1001092
2011
Matthews GV; Dore GJ, 2011, 'Optimal duration of treatment for acute hepatitis c in human immunodeficiency virus-positive individuals?', Hepatology, 53, pp. 1055 - 1056, http://dx.doi.org/10.1002/hep.24152
2011
Audsley J; Seaberg E; Sasadcusz J; Matthews G; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson RJ; Hwang H; Littlejohn M; Locarnini S; Dore GJ; Thio C; Lewin S, 2011, 'Factors associated with elevated ALT in an international HIV/HBV Co-Infected cohort on long-term HAART', PLoS One, 6, pp. e26482, http://dx.doi.org/10.1371/journal.pone.0026482
2011
Smith KR; Suppiah V; O''Connor K; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Matthews G; Irving W; Powell E; Riordan S; Ahlensteil G; Stewart GJ; Bahlo M; Booth DR; George J, 2011, 'Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort', Genome Medicine, 3, pp. 57
2011
Iser D; Avihingsanon A; Wisedopas N; Thompson AJ; Boyd A; Matthews G; Locarnini S; Slavin J; Desmond PV; Lewin S, 2011, 'Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression', AIDS, 25, pp. 197 - 205, http://dx.doi.org/10.1097/QAD.0b013e3283410ccb
2011
Dore GJ; Matthews GV; Rockstroh J, 2011, 'Future of hepatitis C therapy: Development of direct-acting antivirals', Current opinion in HIV & AIDS, 6, pp. 508 - 513, http://dx.doi.org/10.1097/COH.0b013e32834b87f8
2011
Matthews G; Manzini P; Hu Z; Khabo P; Maja P; Matchaba G; Sangweni P; Metcalf K; Pool N; Orsega S; Emery S, 2011, 'Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa', AIDS, 25, pp. 1727 - 1735
2011
Hillman R; Pett SL; Marriott D; Carr AD; Cooper DA; Matthews GV; Brew BJ; Milliken S; Botes LP, 2011, 'Participants' perspectives of high resolution anoscopy', Sexual Health, 8, pp. 255 - 256, http://search.informit.com.au/documentSummary;dn=026919938891985;res=IELHEA
2011
Matthews GV; Rockstroh J, 2011, 'HIV and hepatitis C coinfection', Current Opinion in HIV and AIDS, 6, pp. 449 - 450, http://dx.doi.org/10.1097/COH.0b013e32834bbf85
2011
Matthews GV; Dore GJ, 2011, 'HIV and Hepatitis C Co-Infection', , pp. 177 - 184, http://dx.doi.org/10.1002/9781444346343.ch22
2011
Rockstroh J; Matthews G, 2011, 'Editorial introductions', Current Opinion in HIV and AIDS, 6, http://dx.doi.org/10.1097/COH.0b013e32834d219d
2011
Jin F; Prestage G; Matthews G; Zablotska I; Rawstorne PR; Kippax SC; Kaldor JM; Grulich AE, 2010, 'Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia', Sexually Transmitted Infections, 86, pp. 25 - 28, http://dx.doi.org/10.1136/sti.2009.038182
2010
Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; Van Beek IA; McCaughan G; White PA; French R; Rawlinson WD; Lloyd AROLA; Kaldor JM; Dolan K, 2010, 'Effective treatment of injecting drug users with recently acquired hepatitis C virus infection', Gastroenterology, 138, pp. 123 - 135, http://dx.doi.org/10.1053/j.gastro.2009.09.019
2010
Grebely J; Petoumenos K; Matthews G; Haber PS; Marks P; Lloyd AROLA; Kaldor JM; Dore GJ; Hellard M; Dolan K, 2010, 'Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study', Drug and Alcohol Dependence, 107, pp. 244 - 249, http://dx.doi.org/10.1016/j.drugalcdep.2009.09.015
2010
Grebely J; Matthews GV; Petoumenos K; Dore GJ, 2010, 'Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection', Journal of Viral Hepatitis, 17, pp. 896, http://dx.doi.org/10.1111/j.1365-2893.2009.01256.x
2010
van de Laar T; Matthews G; Prins MH; Danta M, 2010, 'Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection', AIDS, 24, pp. 1799 - 1812, http://dx.doi.org/10.1097/QAD.0b013e32833c11a5
2010
Gandhi M; Fox NS; Russo-Stieglitz K; Hanley ME; Matthews G; Rebarber A, 2009, 'Effect of increased body mass index on first-trimester ultrasound examination for aneuploidy risk assessment', Obstetrics and Gynecology, 114, pp. 856 - 859, http://dx.doi.org/10.1097/AOG.0b013e3181b6bfdc
2009
Matthews G; Hellard M; Haber P; Yeung B; Marks PB; Baker D; McCaughan G; Sasadeusz J; White PA; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ; Dolan K, 2009, 'Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in acute hepatitis C', Clinical Infectious Diseases, 48, pp. 650 - 658, http://dx.doi.org/10.1086/596770
2009
van de Laar T; Pybus O; Bruisten S; Brown D; Nelson M; Bhagani S; Vogel M; Baumgarten A; Chaix M; Fisher M; Gotz H; Matthews G; Neifer S; White PA; Rawlinson W; Pol S; Rockstroh J; Coutinho RA; Dore GJ; Dusheiko GM; Danta M, 2009, 'Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men', Gastroenterology, 136, pp. 1609 - 1617, http://dx.doi.org/10.1053/j.gastro.2009.02.006
2009
Matthews G; Hellard M; Dore GJ, 2009, 'Initial Presentation of Acute Hepatitis C Virus (HCV) Infection among HIV-Negative and HIV-Positive Individuals-Experience from 2 Large German Networks on the Study of Acute HCV Infection Reply', Clinical Infectious Diseases, 49, pp. 319 - 319, http://dx.doi.org/10.1086/600059
2009
Matthews G; Seaberg E; Dore GJ; Bowden S; Lewin S; Sasadeusz J; Marks P; Goodman Z; Philp F; Tang Y; Locarnini S; Thio C, 2009, 'Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals', AIDS, 23, pp. 1707 - 1715, http://dx.doi.org/10.1097/QAD.0b013e32832b43f2
2009
Chang JH; Sirivichayakul S; Avihingsanon A; Thompson A; Revill P; Iser D; Slavin J; Buranapraditkun S; Marks P; Matthews G; Cooper DA; Kent SJ; Cameron P; Sasadeusz J; Desmond PV; Locarnini S; Dore GJ; Ruxrungtham K; Lewin S, 2009, 'Impaired Quality of the Hepatitis B Virus (HBV)-Specific T-Cell Response in Human Immunodeficiency Virus Type 1-HBV Coinfection', Journal of Virology, 83, pp. 7649 - 7658
2009
Crane M; Oliver B; Matthews G; Avihingsanon A; Ubolyam S; Markovska V; Chang JJ; Dore GJ; Price P; Visvanathan K; French MA; Ruxrungtham K; Lewin S, 2009, 'Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy', Journal of Infectious Diseases, 199, pp. 974 - 981
2009
Lewin S; Ribiero R; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini S; Ruxrungtham K; Perelson AS; Dore GJ, 2009, 'Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy', Hepatology, 49, pp. 1113 - 1121
2009
Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan G; White PA; Ffrench R; Rawlinson W; Lloyd A; Kaldor J; Dore GJ, 2009, 'Treatment of recent hepatitis C virus infection in a predominantly injection drug user cohort: the ATAHC Study', The Canadian Journal of Addiction, 1, pp. 33 - 33, http://dx.doi.org/10.1097/02024458-200912000-00072
2009
Matthews G; Dore GJ, 2009, 'HIV and hepatitis C co-infection', Asian Biomedicine, 3, pp. 29 - 37
2009
Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; Van Beek I; Kaldor J; Dore GJ, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', DRUG AND ALCOHOL REVIEW, 28, pp. A27 - A27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270916300083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Matthews GV; Hellard M; Dore GJ, 2009, 'Reply', Clinical Infectious Diseases, 49, pp. 319, http://dx.doi.org/10.1086/600059
2009
Matthews G; Grebely J; Dore GJ, 2008, 'The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure', Journal of Hepatology, 49, pp. 305 - 307, http://dx.doi.org/10.1016/j.jhep.2008.06.005
2008
Sasadeusz J; Audsley J; Mijch AM; Baden R; Caro J; Hunter H; Matthews G; McMahon A; Olender S; Siliciano R; Susan A; Lewin S; Thio C, 2008, 'The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients', AIDS, 22, pp. 947 - 955
2008
Stark D; van Hal S; Matthews G; Harkness JL; Marriott D, 2008, 'Invasive amebiasis in men who have sex with men, Australia', Emerging Infectious Diseases, 14, pp. 1141 - 1143
2008
Matthews G; Avihingsanon A; Lewin S; Amin J; Rerknimitr R; Petcharapirat P; Marks PB; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ, 2008, 'A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand', Hepatology, 48, pp. 1062 - 1069
2008
Crane M; Matthews G; Lewin SR, 2008, 'Hepatitis virus immune restoration disease of the liver', Current Opinion in HIV and AIDS, 3, pp. 446 - 452, http://dx.doi.org/10.1097/COH.0b013e3282fdc953
2008
Preiss S; Littlejohn M; Angus PA; Thompson A; Desmond PV; Lewin S; Sasadeusz J; Matthews G; Dore GJ; Shaw T; Sozzi V; Yuen L; Lau GT; Ayres A; Thio C; Avihingsanon A; Ruxrungtham K; Locarnini S; Revill P, 2008, 'Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance', Hepatology, 48, pp. 741 - 749
2008
Matthews G; Dore GJ, 2008, 'HIV and hepatitis C coinfection', Journal of Gastroenterology and Hepatology, 23, pp. 1000 - 1008
2008
Matthews G, 2007, 'The management of HIV and hepatitis B coinfection', Current Opinion in Infectious Diseases, 20, pp. 16 - 21, http://dx.doi.org/10.1097/QCO.0b013e328012c5aa
2007
Matthews G; Hellard M; Kaldor JM; Lloyd AR; Dore GJ, 2007, 'Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al', AIDS, 21, pp. 2112 - 2113, http://dx.doi.org/10.1097/qad.0b013e3282ef3873
2007
van Hal S; Muthiah K; Matthews G; Harkness JL; Stark D; Cooper DA; Marriott D, 2007, 'Declining incidence of intestinal microsporidiosis and reduction in AIDS-related mortality following introduction of HAART in Sydney, Australia', Transactions of the Royal Society of Tropical Medicine and Hygiene, 101, pp. 1096 - 1100
2007
Revill P; Littlejohn M; Ayres A; Yuen L; Colledge D; Bartholomeusz A; Sasaduesz J; Lewin S; Dore GJ; Matthews G; Thio C; Locarnini S, 2007, 'Identification of a novel hepatitis B virus precore/core deletion mutant in HIV-1/hepatitis B virus co-infected individuals.', AIDS, 21, pp. 1701 - 1710
2007
Matthews G; Cooper DA; Dore GJ, 2007, 'Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir', Antiviral Therapy, 12, pp. 119 - 122
2007
Matthews G; Dore GJ, 2007, 'Response to Schmutz et al., `Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapv of hepatitis B in HIV-coinfection`', AIDS, 21, pp. 777 - 778
2007
Matthews GV; Seaberg E; Dore GJ; Lewin SR; Bowden S; Sasadeuz J; Marks P; Hoy J; Locarnini S; Thio CL, 2007, 'Combination of HBV-active antiretroviral therapy influences hbv virological suppression in an international cohort of 120 HIVHBV coinfected individuals', JOURNAL OF HEPATOLOGY, 46, pp. S194 - S194, http://dx.doi.org/10.1016/S0168-8278(07)62108-4
2007
Dore GJ; Hellard M; Matthews G; Haber PS; Shaw D; Yeung B; Petoumenos K; Van Beek IA; Mccaughan GW; Pan Y; Ffrench R; Rowlinson W; Lloyd AR; Kaldor JM, 2007, 'Treatment of recently acquired hepatitis C infection in injecting drug users: Preliminary results from the Australian trial in acute hepatitis C (ATAHC)', Hepatology, 46, pp. 358A - 358A
2007
Matthews G; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio C, 2006, 'Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy', AIDS, 20, pp. 863 - 870
2006
Matthews G; Kronborg I; Dore GJ, 2005, 'Treatment for hepatitis C virus infection among current injection drug users in Australia', Clinical Infectious Diseases, 40, pp. S325 - S329
2005
Nelson M; Matthews G; Brook MG; Main J; BHIVA Coinfection Guideline Committee ; British HIV Association , 2005, 'BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005).', HIV Med, 6 Suppl 2, pp. 96 - 106, http://dx.doi.org/10.1111/j.1468-1293.2005.00300.x
2005
Menon-Johansson AS; Winston A; Matthews G; Portsmouth S; Daniels D, 2005, 'The first point prevalence study of genital Chlamydia trachomatis infection in young male inmates in the UK', International Journal of STD and AIDS, 16, pp. 799 - 801, http://dx.doi.org/10.1258/095646205774988145
2005
Nelson M; Portsmouth S; Stebbing J; Atkins M; Barr A; Matthews G; Pillay D; Fisher M; Bower M; Gazzard B, 2003, 'An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals', AIDS, 17, http://dx.doi.org/10.1097/00002030-200301030-00002
2003
Bell C; Matthews GV; Nelson MR, 2003, 'Non-nucleoside reverse transcriptase inhibitors - An overview', International Journal of STD and AIDS, 14, pp. 71 - 77, http://dx.doi.org/10.1258/095646203321156827
2003
Nelson MR; Matthews G; Brook MG; Main J; British HIV Association , 2003, 'BHIVA guidelines: coinfection with HIV and chronic hepatitis C virus.', HIV Med, 4 Suppl 1, pp. 52 - 62, http://dx.doi.org/10.1046/j.1468-1293.4.s1.2.x
2003
Matthews G; Dore G, 2003, 'Response to Soriano et al., 'Treatment of chronic hepatitis C virus infection: We must target the virus or liver fibrosis?' [3]', AIDS, 17, pp. 2675 - 2676
2003
Matthews G; Dore GJ, 2003, 'Treatment of chronic hepatitis c virus infection: we must target the virus or liver fibrosis (letter)?', AIDS, 17, pp. 2675 - 2676
2003
Matthews G; Dore C, 2003, 'Response to Soriano et al., `Treatment of chronic hepatitis C virusinfection: we must target the virus or liver fibrosis?`', AIDS, 17, pp. I - II
2003
Dean GL; Edwards SG; Ives NJ; Matthews G; Fox EF; Navaratne L; Fisher M; Taylor GP; Miller R; Taylor CB; De Ruiter A; Pozniak AL, 2002, 'Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy', AIDS, 16, pp. 75 - 83, http://dx.doi.org/10.1097/00002030-200201040-00010
2002
Matthews GV; Sabin CA; Mandalia S; Lampe F; Phillips AN; Nelson MR; Bower M; Johnson MA; Gazzard BG, 2002, 'Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: A cohort study', AIDS, 16, pp. 53 - 61, http://dx.doi.org/10.1097/00002030-200201040-00008
2002
Matthews G; Worrall S; Daniels D, 2001, 'Provision of sexual health services in young offender institutions: Is there gender inequality? [2]', International Journal of STD and AIDS, 12, pp. 130 - 131
2001
Matthews GV; Pillay D; Cane P; Ratcliffe D; Gazzard B; Nelson M, 2001, 'Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1', Clinical Infectious Diseases, 33, pp. 2049 - 2054, http://dx.doi.org/10.1086/322655
2001
Matthews GV; Nelson MR, 2001, 'The management of chronic hepatitis B infection', International Journal of STD and AIDS, 12, pp. 353 - 357, http://dx.doi.org/10.1258/0956462011923273
2001
Matthews G; Bower M; Mandalia S; Powles T; Nelson M; Gazzard B, 2000, '012 AIDS‐related lymphoma in the era of HAART', HIV Medicine, 1, pp. 169 - 169, http://dx.doi.org/10.1046/j.1468-1293.2000.00024-23.x
2000
Powles T; Matthews G; Bower M, 2000, 'AIDS related systemic non-Hodgkin's lymphoma', Sexually Transmitted Infections, 76, pp. 335 - 341, http://dx.doi.org/10.1136/sti.76.5.335
2000
Matthews GV; Bower M; Mandalia S; Powles T; Nelson MR; Gazzard BG, 2000, 'Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy', Blood, 96, pp. 2730 - 2734, http://dx.doi.org/10.1182/blood.v96.8.2730
2000
Matthews GV; Moyle GJ; Mandalia S; Bower M; Nelson M; Gazzard BG, 2000, 'Absence of Association Between Individual Thymidine Analogues or Nonnucleoside Analogues and Lipid Abnormalities in HIV-1–Infected Persons on Initial Therapy', Journal of Acquired Immune Deficiency Syndromes, 24, pp. 310 - 315, http://dx.doi.org/10.1097/00042560-200008010-00002
2000
Matthews GV; Bower M; Mandalia S; Powles T; Nelson MR; Gazzard BG, 2000, 'Changes in acquired immunodeficiency syndrome–related lymphoma since the introduction of highly active antiretroviral therapy', Blood, 96, pp. 2730 - 2734, http://dx.doi.org/10.1182/blood.v96.8.2730.h8002730_2730_2734
2000
Matthews GV; Moyle GJ; Mandalia S; Bower M; Nelson M; Gazzard BG, 2000, 'Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy', Journal of Acquired Immune Deficiency Syndromes, 24, pp. 310 - 315, http://dx.doi.org/10.1097/00126334-200008010-00002
2000
Dean G; Edwards S; Navaratne L; Matthews G; Fox E; Wood C; Fisher M; Churchill D; Taylor G; De Ruiter A; Taylor C; Pozniak A, 2000, '014 Does TB treatment alter virological and immunological response to HAART?', HIV Medicine, 1, pp. 170 - 170, http://dx.doi.org/10.1046/j.1468-1293.2000.00024-27.x
2000
Matthews G; Moyle G; Mandalia S; Bower M; Nelson M; Gazzard B, 2000, 'P35 Is there an association between choice of thymidine analogue and lipid abnormalities in HIV‐1‐infected patients?', HIV Medicine, 1, pp. 183 - 183, http://dx.doi.org/10.1046/j.1468-1293.2000.00024-117.x
2000
Matthews G; Ratcliffe D; Cane P; Pillay D; Gazzard B; Nelson M, 2000, 'P34 Failure of sequential nucleoside analogue monotherapy for the treatment of HBV in HIV/HBV co‐infected patients', HIV Medicine, 1, pp. 183 - 183, http://dx.doi.org/10.1046/j.1468-1293.2000.00024-115.x
2000
Nelson MR; Matthews GV, 2000, 'Newer treatment strategies in the management of HIV/AIDS', CME Bulletin Sexually Transmitted Infections and HIV, 4, pp. 3 - 5
2000
Matthews G; Pozniak AL, 1999, 'Opportunistic infections in the era of HAART', Sexually Transmitted Infections, 75, pp. 214 - 217
1999
Matthews G; Gornall R; Saunders NJ, 1997, 'A randomised placebo controlled trial of loop diuretics in moderate/severe pre-eclampsia, following delivery', Journal of Obstetrics and Gynaecology, 17, pp. 30 - 32, http://dx.doi.org/10.1080/01443619750114040
1997
Carney S; Morgan T; Wilson M; Matthews G; Roberts R, 1975, 'Sodium restriction and thiazide diuretics in the treatment of hypertension.', The Medical journal of Australia, 1, pp. 803 - 807, http://dx.doi.org/10.5694/j.1326-5377.1975.tb82051.x
1975
Matthews G; Morgan T, 1973, 'Diuretics and potassium depletion in hypertension', Australian and New Zealand Journal of Medicine, 3, pp. 432
1973
Jackson K; Visvanathan K; Hall S; Burns G; Bonanzinga S; Anagnostou D; Desmond P; Ratnam D; Sievert W; Levy M; Nicoll A; Lubel J; Angus P; Sinclair M; Strasser S; Ngu M; Meredith C; Matthews G; Revill P; Sundararajan V; Vogrin S; Kuchta A; Canchola J; Torres J; Lau J; Thompson A, 2022, 'Serum HBV RNA levels are associated with risk of hepatitis flare after stopping NA therapy in HBeAg-negative patients', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 77, pp. S842 - S842, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000826275104221&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2022
Carson J; Dore G; Lloyd A; Grebely J; Byrne M; Cunningham EB; Amin J; Vickerman P; Martin N; Treloar C; Matthews G; Hajarizadeh B, 2022, 'Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study', in Journal of Hepatology, Elsevier BV, Vol. 77, pp. S565 - S565, http://dx.doi.org/10.1016/s0168-8278(22)01451-9
2022
Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Martinello M; Danta M; Amin J; Law M; George J; Innes H; Dore G, 2022, 'Liver-related mortality among people with hepatitis B and C: a validation study using linked healthcare administrative datasets', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 77, pp. S560 - S560, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000826275103081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2022
Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Martinello M; Danta M; Amin J; Law M; George J; Dore G, 2022, 'Trends in decompensated cirrhosis and hepatocellular carcinoma diagnosis among people with a hepatitis B notification in New South Wales: a population-based data linkage study', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 77, pp. S302 - S302, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000826275101351&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2022
Bourgeois S; Lim Y-S; Gane EJ; Lee HW; Cheng W; Heo J; Kim W; Buti M; Thompson A; Matthews G; Janczewska E; Ryder S; Andrade RJ; Yuan Y; Benlahrech A; Wustner J; Dorrell L; Yuen M-F, 2022, 'IMC-I109V, a novel T cell receptor (TCR) bispecific (ENVxCD3) designed to eliminate HBV-infected hepatocytes in chronic HBV patients: initial data from a first-in-human study', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 77, pp. S872 - S873, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000826275104281&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2022
Hosseini-Hooshyar S; Alavi M; Martinello M; Matthews G; Dore G, 2021, 'Evaluation of the HCV cascade of care among people with HIV/hepatitis C co-infection in New South Wales, Australia: a data linkage study', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, Vol. 24, pp. 19 - 19, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713652900036&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2021
Acheson LS; Murray E; Clifford B; Siefried KJ; Matthews GV; Ezard N, 2019, 'OPTIMISING CARE FOR PEOPLE WHO INJECT DRUGS: A RETROSPECTIVE MEDICAL RECORD REVIEW OF STAPHYLOCOCCUS AUREUS BACTERAEMIA TREATMENT', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S22 - S23, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100057&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2019
Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'Reinfection following successful HCV DAA therapy among people with recent injecting drug use', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E732 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703222&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2019
Doyle J; van Santen D; Iser D; Sasadeusz J; O'reilly M; Harney B; Roney J; Cutts J; Bowring A; Winter R; Medland N; Fairley C; Moore R; Bk T; Hoy J; Gane E; Matthews G; Prins M; Stoove M; Hellard M, 2019, 'Hepatitis C elimination by enhancing care and treatment among HIV co-infected individuals (the co-EC study): Real world evidence of decreasing HCV incidence and prevalence', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E329 - E329, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, http://dx.doi.org/10.1016/S0618-8278(19)30643-7
2019
Harney B; Stoove M; Sacks-Davis R; Van Santen D; Fairley C; Medland N; O'Reilly M; Moore R; Tee B; Sasadeusz J; Iser D; Roney J; Matthews G; Gane E; Prins M; Hellard M; Doyle J, 2019, 'RISK BEHAVIORS FOLLOWING HEPATITIS C TREATMENT AMONG GAY AND BISEXUAL MEN LIVING WITH HIV IN MELBOURNE, AUSTRALIA', in SEXUALLY TRANSMITTED INFECTIONS, BMJ PUBLISHING GROUP, Vol. 95, pp. A117 - A117, http://dx.doi.org/10.1136/sextrans-2019-sti.297
2019
Matthews G; Bhagani S; Van der Valk M; Rockstroh JK; Kim AY; Thurnheer C; Feld JJ; Bruneau J; Gane EJ; Hellard M; Grebely J; Applegate T; Marks P; Martinello M; Petoumenos K; Dore G, 2019, 'SHORT COURSE DURATION SOFOSBUVIR/VELPATASVIR IS INFERIOR TO STANDARD DURATION THERAPY IN THE TREATMENT OF RECENTLY ACQUIRED HCV INFECTION: RESULTS FROM REACT STUDY', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 1487A - 1488A, presented at 70th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000500824000056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2019
Acheson LS; Murray E; Clifford B; Siefried KJ; Matthews GV; Ezard N, 2019, 'Optimising care for people who inject drugs: A retrospective medical record review of staphylococcus aureus bactaraemia treatment', in Drug and Alcohol Review, Wiley, Hobart, Australia, Vol. 38, presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference, Hobart, Australia, 10 November 2019 - 13 November 2019, http://dx.doi.org/10.1111/dar.12991
2019
van Santen D; Hoy J; Agius P; Iser D; O'reilly M; Sasadeusz J; Stoove M; Roney J; Moore R; Bk T; Medland N; Fairley C; Gane E; Matthews G; Prins M; Hellard M; Doyle J, 2019, 'Changes in liver stiffness measurements following DAA treatment among HIV/HCV-coinfected individuals: Does HIV contribute to liver disease after HCV cure?', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E204 - E204, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481700380&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2019
Martinello M; Bartlett S; Dore G; Bopage R; Finlayson R; Baker D; Bloch M; Doyle J; Shaw D; Hajkowicz K; Read P; Filep E; Lin L; Yee J; Applegate T; Hellard M; Matthews G, 2018, 'Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia', in Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia, Paris, France, presented at THE INTERNATIONAL LIVER CONGRESS 2018, Paris, France, 11 April 2018 - 15 April 2018
2018
Yee J; Dore GJ; Hanson J; Iser D; Danta M; Shaw D; Read P; Balcomb A; Post J; Faros J; Montebello M; Collie P; Hallinan R; Cooper L; Marks P; Hajarizadeh B; Matthews GV, 2018, 'High efficacy of HCV therapy following universal DAA access in Australia: the REACH-C cohort', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, Vol. 25, pp. 54 - 54, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2018
Martinello M; Cerrone M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Schoolmeesters A; Grebely J; Nelson M; Matthews GV, 2018, 'TARGET3D: high efficacy of 8 weeks paritaprevir/ritonavir/ombitasvir and dasabuvir among people with recent genotype 1 HCV infection', in HIV MEDICINE, WILEY, Vol. 19, pp. S151 - S152, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000430174700440&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2018
Dalgard O; Grebely J; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and Velpatasvir for Hepatitis C Virus Infection in People with Recent Injecting Drug Use (Simplify): An Open-Label, Single-Arm, Phase 4, Multicentre Trial', in HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, PACINI EDITORE, Vol. 20, pp. 14 - 14, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440974900004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2018
Salazar-Vizcaya L; Boettiger DC; Dore GJ; Gray R; Law M; Rauch A; Lea T; Matthews G, 2018, 'Will hepatitis C transmission be eliminated by 2025 among HIV-positive men who have sex with men in Australia?', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, Vol. 21, pp. 66 - 66, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440002700139&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2018
Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Wilcox A; Filep E; Hellard M; Matthews GV, 2017, 'DAA treatment scale-up in HIV/HCV co-infection: characterisinga population at risk for reinfection', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S495 - S496, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31388-0
2017
Milder TY; Greenfield J; Matthews G; Center J, 2017, 'Hypophosphataemic osteomalacia induced by tenofovir disoproxil fumarate', in CLINICAL ENDOCRINOLOGY, WILEY, AUSTRALIA, Perth, Vol. 89, pp. 70 - 70, presented at Joint Annual Scientific Meetings of Endocrine-Society-of-Australia (ESA) and Society-for-Reproductive-Biology (SRB), AUSTRALIA, Perth, 27 August 2017 - 30 August 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000436537900157&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2017
Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer CM; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S513 - S513, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401056601271&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2017
Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin AH; Dillon JF; Read P; Gane ED; Dore GJ, 2017, 'EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR IN PEOPLE WITH CHRONIC HEPATITIS C VIRUS INFECTION AND RECENT INJECTING DRUG USE: THE SIMPLIFY STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 36, pp. 34 - 34, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2017
Bartlett SR; Grebely J; Eltahla AA; Reeves JD; Howe A; Miller V; Bull RA; Ceccherini-Silberstein F; Douglas MW; Dore GJ; Harrington P; Lloyd AR; Jacka B; Matthews GV; Wang GP; Pawlotsky J-M; Feld JJ; Schinkel J; Garcia F; Lennerstrand J; Applegate TL, 2017, 'Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S323 - S323, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30970-4
2017
Bowing AL; Doyle JS; Iser DM; Sasadeusz J; Roney J; O'Reilly M; Fairley C; Gane E; Hoy J; Matthews GV; Medland N; Moore R; Prins M; Stoove M; Ban-Kiem T; Hellard ME, 2017, 'High-risk behaviour in a cohort of HIV/hepatitis C coinfected gay and bisexual men commencing hepatitis C treatment', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S269 - S270, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30852-8
2017
Martinello M; Bhagani S; Gane EJ; Orkin C; Cooke G; Kulasegaram R; Shaw D; Hellard M; Tu E; Filep E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews G, 2017, 'Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 574A - 575A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089801215&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2017
Doyle JS; Bowring AL; Iser DM; Sasadeusz J; Roney J; O'Reilly M; Fairley C; Gane E; Hoy J; Matthews GV; Medland N; Moore R; Prins M; Stoove M; Ban-Kiem T; Hellard ME, 2017, 'Suitability of HCV treatment in primary care settings for individuals with HIV/hepatitis C coinfection', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S524 - S525, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31450-2
2017
Martinello M; Petoumenos K; Grebely J; Gane E; Hellard M; Shaw D; Sasdeusz J; Applegate T; Lamoury F; Yeung B; Maire L; Dore G; Matthews G, 2016, 'INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S620 - S621, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01152-1
2016
Hill AM; Roberts T; Amorosa V; Pourmand K; Matthews G; Cooke G; Khan H; Main J; Brown A; Peter JA; Nelson DR; Fried MW; Cohn J; Graham CS, 2015, 'Can HCV Antigen Testing Replace HCV RNA PCR Analysis, for Diagnosis and Monitoring of Treatment for Hepatitis C?', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, Vol. 62, pp. 1099A - 1100A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368375404073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2015
Clifford B; Acheson LS; Brener L; Siefried KJ; Steele M; Matthews G; Ezard N, 2022, 'A qualitative exploration of client and healthcare provider perspectives on why people who inject drugs with injecting-related infections discharge against medical advice', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S43 - S44, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2022
Hall S; Burns G; Anagnostou D; Vogrin S; Sundararajan V; Ratnam D; Levy M; Lubel J; Nicoll A; Strasser S; Sievert W; Desmond P; Ngu M; Angus P; Sinclair M; Meredith C; Matthews G; Revill P; Jackson K; Bowden S; Locarnini S; Visvanathan K; Thompson A, 2021, 'Low baseline HBsAg levels predict disease remission and HBsAg loss after stopping nucleot(s)ide analogs in chronic hepatitis B e-antigen-negative patients: Final results of the HBV-STOP study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 65 - 65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693377800107&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2021
Hall S; Burns G; Anagnostou D; Vogrin S; Sundararajan V; Ratnam DT; Levy MT; Lubel JS; Nicoll AJ; Strasser SI; Sievert W; Desmond PV; Ngu MC; Angus PW; Maree S; Meredith C; Matthews G; Revill P; Jackson K; Bonanzinga S; Canchola J; Kuchta A; Torres J; Bowden S; Locarnini S; Visvanathan K; Thompson A, 2021, 'FINAL RESULTS OF THE HBV-STOP STUDY - LOW BASELINE HBsAg LEVELS PREDICT DISEASE REMISSION AND HBsAg LOSS AFTER STOPPING NUCLEOT(S)IDE ANALOGUES IN CHRONIC HEPATITIS B E-ANTIGEN NEGATIVE PATIENTS', in HEPATOLOGY, WILEY, pp. 482A - 483A, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000707188002197&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2021
Cysique LA; Allen-Davidian Y; Darley DR; Byrne A; Wilhelm K; Dore G; Matthews G; Brew BJ, 2021, '032 Cognitive deficits are associated with anosmia but not anxio-depressive symptoms in COVID-19', in BMJ Neurology Open, BMJ, pp. a12 - a12, presented at Oral abstracts, http://dx.doi.org/10.1136/bmjno-2021-anzan.32
2021
Morphett K; Puljevic C; Boyd M; Bonevski B; Gilks C; Borland R; Courtney R; Mcrobbie H; Baker P; Winston A; Baker AL; Matthews G; Chatfield M; Farrell M; Mattick RP; Ferguson S; Blakely T; Hall WD; Gartner C, 2021, 'A PRAGMATIC RANDOMISED PARTIAL CROSSOVER CLINICAL TRIAL OF NICOTINE VAPORISERS ADDED TO STANDARD CARE FOR SMOKING CESSATION AND RELAPSE PREVENTION AMONG PRIORITY POPULATIONS WITH COMORBIDITIES', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S15 - S15, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200031&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2021
Casey J; MacParland S; Zahoor A; Janssen HLA; Matthews G; Marks P; Grebely J; Dore G; Hansen BE; Kaul R; Chua C; Gehring AJ; Feld JJ, 2020, 'RESTORATION OF HCV-SPECIFIC T CELLS FOLLOWING DAA THERAPY IN ACUTE HCV INFECTION-SUPPORT FOR TREATMENT OF ACUTE INFECTION.', in HEPATOLOGY, WILEY, ELECTR NETWORK, pp. 613A - 614A, presented at Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 November 2020 - 16 November 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000574027002142&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2020
Bradshaw D; Vasylyeva T; Davis C; Pybus O; Theze J; Thomson E; Martinello M; Matthews G; Burholt R; Gilleece Y; Cooke G; Page E; Waters L; Nelson M, 2019, 'Risk factors and patterns of HCV transmission amongst men who have sex with men', in HIV MEDICINE, WILEY, pp. 12 - 12, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463022600024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2019
Walsh KW; Martinello M; Churkin A; Lou S; Applegate T; Etzion O; Uprichard SL; Cotler SJ; Barash D; Matthews G; Dahari H, 2019, 'MODELING INDICATES 100% NEGATIVE PREDICTIVE VALUE OF ACHIEVING CURE IN SUBJECTS WITH RECENT HCV INFECTION TREATED FOR 6 WEEKS WITH SOFOSBUVIR AND RIBAVIRIN: THE DARE II STUDY', in HEPATOLOGY, WILEY, MA, Boston, pp. 969A - 970A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653503298&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2019
Artenie AA; Cunningham E; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Applegate TL; Dillon JF; Fraser C; Gane E; Litwin AH; Marks P; Matthews GV; Quiene S; Thurnheer MC; Weltman M; Dore G; Bruneau J; Grebely J, 2018, 'Drug and alcohol use patterns during and following treatment with sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use: Insights from trajectory analyses', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, pp. 31 - 32, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2018
Doyle J; Iser D; Sasadeusz J; Roney J; Cutts J; Bowring A; Winter R; O'reilly M; Fairley C; Gane E; Hoy J; Matthews G; Medland N; Moore R; Prins M; Tee B; Stoove M; Hellard M, 2018, 'Hepatitis C treatment success in primary and tertiary care among people with HCV/HIV coinfection', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S314 - S314, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30846-8
2018
Lamoury F; Hajarizadeh B; Martinello M; Soker A; Martinez D; Cunningham P; Cloherty GA; Marks P; Matthews G; Amin J; Grebely J; Dore G; Applegate TL, 2016, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool among those with recent Hepatitis C virus infection, including for post-treatment relapse', in HEPATOLOGY, WILEY, MA, Boston, pp. 415A - 415A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2016
Barr E; Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews G; Saag MS; Zamor P; Orkin C; Gress J; Shaughnessy M; Klopfer S; Howe A; Wahl J; Nguyen BY; Robertson M; Platt HL; Sulkowski M, 2016, 'High efficacy of elbasvir/grazoprevir (EBR/GZR) in HCV genotype 1, 4, and 6-infected patients with HIV coinfection: SVR24 data from the phase 3 C-EDGE Coinfection study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 66 - 66, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000384664700121&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2016
Waziry RK; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews G; Law M; Dore G; Law M, 2015, 'Trends in end-stage liver disease among people notified with HBV or HCV in New South Wales, Australia: 2000-2014', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1121A - 1121A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015
2015
Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews G; Saag MS; Zamor P; Orkin C; Gress J; Shaughnessy M; Klopfer S; Platt HL; Robertson M; Sulkowski M, 2015, 'High efficacy of grazoprevir/elbasvir in HCV genotype 1, 4 and 6-infected patients with HIV co-infection: the phase 3 C-EDGE co-infection study', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, http://dx.doi.org/10.7448/IAS.18.5.20545
2015
Rockstroh JK; Nelson M; Katlama C; Lalezari JP; Mallolas J; Bloch M; Matthews G; Saag M; Zamor PJ; Orkin C; Gress J; Shaughnessy M; Klopfer S; Howe AY; Wahl J; Nguyen B-YT; Barr E; Platt HL; Robertson M; Sulkowski MS, 2015, 'High Efficacy of Grazoprevir/Elbasvir (GZR/EBR) in HCV Genotype 1, 4, and 6-infected Patients With HIV Coinfection: SVR24 Data From the Phase 3 C-EDGE Coinfection Study', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 317A - 317A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368375401095&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2015
Sheridan DA; Hajarizadeh B; Matthews G; Applegate TL; Douglas MW; Askew B; Neely D; Bassendine MF; Dore GJ; Lloyd AR; George J; Grebely J, 2014, 'Hepatitis C lipoviral particle levels are associated with spontaneous clearance of acute infection', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 929A - 929A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014
2014
Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2014, 'The impact of ribavirin plasma concentration on the eficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', in Antiviral Therapy, SAGE Publications, MA, Boston, pp. 127 - 132, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, http://dx.doi.org/10.3851/IMP2984
2014
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2014, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies', in Antiviral Therapy, SAGE Publications, MA, Boston, pp. 425 - 434, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, http://dx.doi.org/10.3851/IMP3035
2014
Bradshaw D; Jacka B; Sacks-Davis R; Lamoury F; Applegate T; Dore G; Down I; Luciani F; Hellard M; Sasadeusz J; Danta M; Matthews G, 2014, 'A novel method comparing sexual networks with the HCV phylogeny in HIV-positive MSM with acute HCV infection identifies two potential intervention targets for permucosally transmitted HCV in Australia', in HIV MEDICINE, WILEY-BLACKWELL, pp. 136 - 136
2014
Doyle JS; Dore GJ; Shaw D; Grebely J; Erratt A; Hellard M; Matthews G, 2014, 'HCV re-infection rates are low after long-term follow up of acute HCV infection: The Australian Trial of Acute Hepatitis C Recall study', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 915A - 915A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2014
Doyle JS; Deterding K; Grebely J; Wedemeyer H; Davis RS; Matthews G; Rice T; Morris M; McGovern BH; Kim AY; Bruneau J; Lloyd AR; Page K; Manns M; Hellard ME; Dore GJ; Group IS, 2013, '811 RESPONSE TO TREATMENT FOLLOWING RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s332, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/s0168-8278(13)60813-2
2013
Holmes JA; Bonanzinga S; Roberts SK; Sievert W; Dore GJ; McCaughan G; Crawford DH; Cheng WS; Weltman MD; Matthews G; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Thompson AJ, 2013, 'THE ASSOCIATION BETWEEN HAEMOGLOBIN DECLINE AND SVR IS INDEPENDENT OF ITPA GENOTYPE DURING PEG-INTERFERON PLUS RIBAVIRIN THERAPY FOR HCV-1: ANALYSIS FROM THE CHARIOT STUDY', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s189 - s190, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/s0168-8278(13)60464-x
2013
Bradshaw D; Lamoury F; Catlett B; Applegate TL; Mcallister J; Dore GJ; Matthews G; Danta M, 2013, 'Seminal HCV RNA level may mirror dynamics of plasma HCV RNA in HIV-positive men with acute HCV infection', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 913A - 913A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013
2013
Bradshaw D; Jacka B; Sacks-Davis R; Lamoury F; Applegate TL; Dore GJ; Down I; Luciani F; Hellard M; Sasadeusz J; Danta M; Matthews G, 2013, 'A novel method comparing sexual networks with the HCV phylogeny in HIV-positive men who have sex with men (MSM) with acute HCV infection identifies two potential intervention targets for permucosally-transmitted HCV', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 1307A - 1307A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013
2013
Danta M; How-Chow D; McInnes E; Matthews G; Dore GJ, 2013, 'Growing burden of HCV-related advanced liver disease related to enhanced Fibroscan-based screening', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 956A - 957A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330252204331&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2013
Achhra AC; Boyd M; Law MG; Matthews G; Kelleher AD; Cooper DA, 2013, 'Sequencing antiretroviral therapy to maximize patient safety: could we move away from ritonavir, abacavir, tenofovir and efavirenz (RATE) - agents that concern prescribers and patients? A feasibility study and call for a trial', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, BELGIUM, Brussels, pp. A51 - A51, presented at 15th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, BELGIUM, Brussels, 15 October 2013 - 17 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335230200056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2013
Grebely J; Feld JJ; Applegate T; Matthews G; Hellard M; Sherker A; Petoumenos K; Shaw I; Yeung B; Kaldor JM; Cherepanov V; Bruneau J; Lloyd A; Shoukry N; Dore G, 2012, '889 PLASMA IP10 LEVEL PREDICTS SPONTANEOUS CLEARANCE IN ACUTE HCV INFECTION', in Journal of Hepatology, Elsevier, SPAIN, Barcelona, pp. s346, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012, http://dx.doi.org/10.1016/s0168-8278(12)60901-5
2012
Matthews G; Applegate TL; Tschochner M; Plauzolles A; Mallal SA; Grebely J; Hellard M; Lloyd AR; Kaldor JM; Dore GJ; Gaudieri S, 2011, 'ULTRA DEEP SEQUENCING ANALYSIS OF TREATMENT NAIVE INDIVIDUALS WITH RECENTLY ACQUIRED HEPATITIS C INFECTION DEMONSTRATES WIDESPREAD AMINO ACID VARIATION AT KEY PROTEASE AND POLYMERASE SITES OCCURRING AT LOW FREQUENCY', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1343A - 1344A, presented at 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 04 November 2011 - 08 November 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000295578004555&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Grebely J; Matthews GV; Hellard M; Suppiah V; Petoumenos K; Applegate T; Yeung B; Rawlinson W; Feld J; Lloyd AR; Booth D; Kaldor JM; George J; Dore GJ, 2011, 'IL28B GENOTYPE HAS VARIABLE INFLUENCE ON EARLY VIRAL KINETICS, BUT NO INFLUENCE ON SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S524 - S524, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)61330-5
2011
Ali RJ; Roberts SK; Ray J; Sievert W; McCaughan G; Weltman M; Crawford D; Cheng W; Rawlinson W; Thommes J; Rizkalla B; Yoshihara M; Dore GJ; Matthews GV, 2011, 'EARLY ON-TREATMENT PLASMA RIBAVIRIN CONCENTRATIONS ARE ASSOCIATED WITH ON-TREATMENT ANAEMIA AND TREATMENT OUTCOME IN CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S161 - S161, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)60403-0
2011
Gaudieri S; Applegate T; Tshochner M; Plauzolles A; Pfafferott K; Lucas M; Diepolder H; Ulsenheimer A; Mallal S; Grebely J; Hellard M; Lloyd A; Kaldor J; Dore G; Matthews G, 2011, 'SIGNATURE RESISTANCE MUTATIONS TO DIRECTLY ACTING ANTIVIRAL AGENTS OCCUR AT LOW PREVALENCE IN TREATMENT NAIVE SUBJECTS WITH RECENTLY ACQUIRED HEPATITIS C INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S184 - S185, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)60455-8
2011
Grebely J; Alavi M; Haber P; Day C; Matthews GV; van Beek I; Walsh N; Yeung B; Petoumenos K; Dolan K; Spelman T; Kaldor JM; Dore GJ; Hellard M, 2011, 'IMPACT OF TREATMENT ON INJECTING DRUG USE BEHAVIORS DURING RECENT HCV INFECTION: THE ATAHC STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S174 - S174, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)60431-5
2011
Applegate T; Gaudieri S; Pham S; White P; Grebely J; Hellard M; Suppiah V; George J; Lloyd A; Dore G; Matthews GV, 2011, 'Impact of host and viral characteristics on treatment outcome within hepatitis C transmission clusters in HIV-positive individuals with recently acquired HCV', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, pp. A87 - A87, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000687677600071&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Gaudieri S; Applegate T; Tschochner M; Plauzolles A; Pfafferott K; Lucas M; Diepolder H; Ulsenheimer A; Mallal S; Grebely J; Hellard M; Lloyd A; Kaldor J; Dore G; Matthews GV, 2011, 'Signature resistance mutations to directly acting antiviral agents occur at low prevalence in treatment-naive subjects with recently acquired hepatitis C infection', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, pp. A86 - A86, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000687677600070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Feld JJ; Grebely J; Applegate T; Matthews GV; Hellard M; Suppiah V; Sherker A; Petoumenos K; Shaw I; Yeung B; Rawlinson W; Booth D; Kaldor JM; Lloyd AR; Dore GJ, 2011, 'IP-10 IS ASSOCIATED WITH EARLY VIRAL KINETICS, BUT NOT SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S455 - S455, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)61154-9
2011
Applegate T; Gaudieri S; Pham S; White P; Grebely J; Hellard M; Suppiah V; George J; Lloyd A; Dore G; Matthews GV, 2011, 'Impact of host and viral characteristics on treatment outcome within hepatitis C transmission clusters in HIV-positive individuals with recently acquired HCV', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Los Cabos, MEXICO, pp. A87 - A87, presented at International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Los Cabos, MEXICO, 07 June 2011 - 11 June 2011, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294375700092&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Ali RJ; Bowden S; Avihingsanon A; Lewin SR; Ruxrungtham K; Locarnini S; Sasadeusz J; Dore GJ; Matthews G, 2011, 'CHANGES IN QUANTITATIVE HBSAG AND HBEAG PREDICT HBV TREATMENT RESPONSE IN HBV/HIV COINFECTED INDIVIDUALS ON TENOFOVIR BASED HAART IN THAILAND', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1081A - 1081A, presented at 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 04 November 2011 - 08 November 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000295578003739&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Gaudieri S; Applegate T; Tschochner M; Plauzolles A; Pfafferott K; Lucas M; Diepolder H; Ulsenheimer A; Mallal S; Grebely J; Hellard M; Lloyd A; Kaldor J; Dore G; Matthews GV, 2011, 'Signature resistance mutations to directly acting antiviral agents occur at low prevalence in treatment-naive subjects with recently acquired hepatitis C infection', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Los Cabos, MEXICO, pp. A86 - A86, presented at International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Los Cabos, MEXICO, 07 June 2011 - 11 June 2011, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294375700091&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore GJ, 2010, 'WEEK 4 HCV RNA IS THE OPTIMAL PREDICTOR OF SVR IN BOTH HIV POSITIVE AND NEGATIVE SUBJECTS WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S116 - S116, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 14 April 2010 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)60278-4
2010
Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore G, 2010, 'DIFFERENCES IN EARLY VIROLOGICAL DECLINE IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV SUGGEST A POTENTIAL BENEFIT FOR THE USE OF RIBAVIRIN', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, pp. S28 - S28, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 14 April 2010 - 18 April 2010, http://www.journal-of-hepatology.eu/article/S0168-8278(10)60062-1/abstract
2010
Matthews GV; Alavi M; Grebely J; Petoumenos K; Yeung B; Hellard M; Lloyd A; van Beek I; Kaldor J; Haber P; Dore GJ, 2010, 'Depression prior to and during treatment for recent hepatitis C virus (HCV) infection among HCV and HCV/HIV participants in the ATAHC study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A21 - A21, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431200041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2010
Matthews GV; Alavi M; Grebely J; Petoumenos K; Yeung B; Hellard M; Lloyd A; van Beek I; Kaldor J; Haber P; Dore GJ, 2010, 'Depression prior to and during treatment for recent hepatitis C virus (HCV) infection among HCV and HCV/HIV participants in the ATAHC study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A21 - A21, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431500027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2010
Audsley J; Seaberg E; Sasadeusz J; Matthews GV; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson R; Hwang HS; Littlejohn M; Dore GJ; Locarnini S; Thio CL; Lewin SR, 2010, 'Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A53 - A53, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431200068&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2010
Audsley J; Seaberg E; Sasadeusz J; Matthews GV; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson R; Hwang HS; Littlejohn M; Dore GJ; Locarnini S; Thio CL; Lewin SR, 2010, 'Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A53 - A53, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431500054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2010
Iser DM; Boyd A; Avihingsanon A; Thompson AJ; Nguyen T; Matthews GV; Bowden S; Locarnini SA; Slavin J; Desmond PV; Dore GJ; Ruxrungtham K; Lewin SR, 2009, 'No increase in intrahepatic mononuclear or stellate cell activation in HIV-HBV co-infected individuals', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A292 - A292, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270551200196&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Iser DM; Boyd AJ; Avihingsanon A; Thompson AL; Nguyen T; Matthews G; Bowden S; Locarnini S; Slavin J; Desmond PV; Dore GJ; Ruxrungtham K; Lewin SR, 2009, 'NO INCREASE IN INTRAHEPATIC MONONUCLEAR CELL OR STELLATE CELL ACTIVATION IN HIV-HBV CO-INFECTED INDIVIDUALS WITH ADVANCED HIV AND MILD LIVER DISEASE', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 993A - 994A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001493&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan GW; White PA; Ffrench RA; Rawlinson W; Lloyd AR; Kaldor J, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 723A - 723A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000887&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Matthews G; Grebely J; Pham ST; Hellard M; Marks P; Rawlinson W; Kaldor J; Lloyd AR; White PA; Dore GJ, 2009, 'EPIDEMIOLOGY OF RECENTLY ACQUIRED HEPATITIS C VIRUS (HCV) INFECTION IN HCV AND HCV/HIV INFECTED PARTICIPANTS IN THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 668A - 668A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000775&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Matthews G; Hellard M; Haber PS; Yeung B; Marks PB; Sasadcusz J; Baker DA; McCaughan G; White PA; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Frequency of RVR and its utility as a predictor of treatment outcome in individuals treated within the Australian Trial in Acute Hepatitis c (ATAHC)', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. S303 - S303, presented at Journal of Hepatology
2008
Matthews G; White PA; Hellard M; Grebely J; Marks P; Yeung B; Kaldor JM; Lloyd AR; Danta M; Dore GJ, 2008, 'Evidence of sexual transmission of hepatitis C virus infection among HIV-positive men who have sex with men in the Australian trial in acute hepatitis C (ATAHC) study', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A365 - A366
2008
Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Thio C; Bowden SJ; Ayres A; Locarnini S; Ruxrungtham K; Dore GJ, 2008, 'Tenofovir based HAART is associated with high rates of HBV DNA suppression and HBEAG seroconversion in thai HIV-HBV coinfected patients', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A336 - A336, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2008
Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks P; Revill PA; Ayres A; Bow-den S; Locarnini S; Thio CL; Ruxrungtham K; Dore GJ, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in HEPATOLOGY, JOHN WILEY & SONS INC, CA, San Francisco, pp. 712A - 713A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, CA, San Francisco, 31 October 2008 - 04 November 2008, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757401290&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2008
White PA; Grebely J; Flynn J; Matthews G; Renkin M; Yeung B; Rawlinson WD; Kaldor JM; Hellard M; Lloyd AR; Ffrench R; Dore GJ, 2008, 'NATURAL HISTORY OF HCV SUPERINFECTION AND REINFECTION', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1056 - 1057, presented at Hepatology
2008
Matthews G; Grebely J; White PA; Renkin M; Marks PB; Ffrench R; Rawlinson WD; Kaldor JM; Hellard M; Lloyd AR; Dore GJ, 2008, 'INCIDENCE AND RISK FACTORS FOR HCV SUPERINFECTION AND REINFECTION IN INDIVIDUALS TREATED FOR ACUTE/EARLY CHRONIC HCV INFECTION', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1844 - 1845, presented at Hepatology
2008
White PA; Grebely J; Matthews G; Flynn J; Renkin M; Kaldor JM; Lloyd AR; Hellard M; Ffrench R; Dore GJ, 2008, 'Natural history of HCV reinfection and superinfection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A355 - A355
2008
Matthews G; Hellard M; Haber PS; Yeung B; Marks P; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Frequency of rapid virological response and its utility as a predictor of treatment outcome in individuals treated within the Australian trial in acute hepatitis C (ATAHC)', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A337 - A337
2008
Grebely J; Matthews G; White PA; Renkin M; Flynn J; Ffrench R; Kaldor JM; Hellard M; Lloyd AR; Dore GJ, 2008, 'Incidence and risk factors for HCV reinfection and superinfection in individuals treated for acute/early chronic HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A343 - A344
2008
Hellard M; Matthews G; Petoumenos K; Grebely J; Haber PS; Van Beek IA; Marks P; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Factors associated with uptake of treatment for acute and early chronic hepatitis C virus infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A344 - A344
2008
Hellard M; Grebely J; Matthews G; Haber PS; Petoumenos K; Yeung B; Van Beek IA; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Impact of illicit drug use on response to therapy during treatment for acute and early chronic HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A337 - A338
2008
Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks PB; Revill P; Ayres A; Bow-den S; Locarnini S; Thio C; Ruxrungtham K; Dore GJ, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 906 - 907, presented at Hepatology
2008
Hellard M; Dore G; Haber P; Marks P; Matthews G; Yeung B; Nguyen O; Pan Y; Ffrench R; McCaughan G; Van Beek I; White P; Dolan K; Rawlinson W; Lloyd A; Kaldor J, 2006, 'Australian trial in acute hepatitis C: preliminary findings', in JOURNAL OF CLINICAL VIROLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S139 - S139, presented at 12th International Symposium on Viral Hepatitis and Liver Disease, FRANCE, Paris, 01 July 2006 - 05 July 2006, http://dx.doi.org/10.1016/S1386-6532(06)80430-0
2006
Hellard M; Haber P; Day C; Marks P; Matthews G; Yeung B; Nguyen O; Dolan K; Van Beek I; Kaldor J; Dore G, 2006, 'Australian trial in acute hepatitis C: baseline behavioural data', in JOURNAL OF CLINICAL VIROLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S140 - S140, presented at 12th International Symposium on Viral Hepatitis and Liver Disease, FRANCE, Paris, 01 July 2006 - 05 July 2006, http://dx.doi.org/10.1016/S1386-6532(06)80434-8
2006
Martinello M; Hajarizadeh B; Grebely J; Matthews G; Dore G, 2019, 'Cure and Control: What Will It Take to Eliminate HCV?', in Sofia M (ed.), HCV: The Journey from Discovery to a Cure: Volume II, Springer International Publishing, pp. 447 - 490, http://dx.doi.org/10.1007/7355_2018_56
2019
Matthews G; Martinello MK; van Beek I; Burns M, 2014, 'Exposure and acute viral hepatitis', in HIV, Viral Hepatitis and STIs: A Guide for Primary Care
2014
Price V, 2014, 'HIV, viral hepatitis and STIs: a guide for primary care', in Burke M; Matthews G; Dore G; Cowie B (ed.), , Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Sydney, https://www.ashm.org.au/products/product/1976963411
2014
Matthews G; Dore GJ, 2009, 'HIV and hepatitis C co-infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 308 - 329
2009
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments', presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30899-1
2017
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews G; Law M; Dore G; Law M, 2016, 'Survival following hepatocellular carcinoma among people with HBV or HCV in New South Wales, Australia between 2000 and 2014', presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016
2016
Hajarizadeh B; Grebely J; Matthews G; Martinello M; Dore G, 2016, 'Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments', presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016
2016
Matthews GV; Kaur A; Ray JE; Graham GG; Egan B; Williams KM; Day RO, 2013, 'USE OF A POPULATION PHARMACOKINETIC MODEL TO PREDICT WEEK 4 RIBAVIRIN LEVELS FROM EARLY CONCENTRATIONS', NETHERLANDS, Amsterdam, Vol. 58, pp. S357 - S357, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)60872-7
2013

NHMRC CDF Level 1 2013

NHMRC CDF Level 2 2019

UNSW Scientia Fellow 2019